<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEVOFLOXACIN
                         - levofloxacin tablet, film coated </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use levofloxacin safely and effectively. See full prescribing information for levofloxacin tablets.<br><br>Levofloxacin Tablet, Film Coated for Oral use<br>Initial U.S. Approval: 1996</div>
<div class="Warning"><div><h1 class="Warning">
<br><span class="Bold">WARNING<br><br><span class="Italics">See full prescribing information for complete boxed warning.</span></span><br><span class="Bold"><br>Fluoroquinolones, including levofloxacin, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants <span class="Italics">[see </span><span class="Italics"><a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.</span><br><span class="Bold"><br>Fluoroquinolones, including </span><span class="Bold">levofloxacin, may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid levofloxacin in patients with a known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span></span>
</h1></div></div>
<div><div><p class="Highlighta"><br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.  (<a href="#section-1">1</a>)</p></div></div>
<div></div>
<div class="Warning"><div><h1 class="Warning">
<br><span class="Bold">WARNING<br><br><span class="Italics">See full prescribing information for complete boxed warning.</span></span><br><span class="Bold"><br>Fluoroquinolones, including levofloxacin, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants <span class="Italics">[see </span><span class="Italics"><a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.</span><br><span class="Bold"><br>Fluoroquinolones, including </span><span class="Bold">levofloxacin, may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid levofloxacin in patients with a known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span></span>
</h1></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"><br>Levofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by designated, susceptible bacteria <a href="#Section_1">(1</a>, <a href="#Section_12.4">12.4)</a>.<br> </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: nosocomial <a href="#Section_1.1">(1.1)</a> and community acquired <a href="#Section_1.2">(1.2</a>, <a href="#Section_1.3">1.3)</a>
</li>
<li>Acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> <a href="#Section_1.4">(1.4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute bacterial exacerbation of chronic bronchitis</span> <a href="#Section_1.5">(1.5)</a>
</li>
<li>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: complicated <a href="#Section_1.6">(1.6)</a> and uncomplicated <a href="#Section_1.7">(1.7)</a>
</li>
<li>Chronic bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span> <a href="#Section_1.8">(1.8)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span>: complicated <a href="#Section_1.9">(1.9</a>, <a href="#Section_1.10">1.10)</a> and uncomplicated <a href="#Section_1.13">(1.12)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute pyelonephritis</span> <a href="#Section_1.11">(1.11)</a>
</li>
<li>Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>, post-exposure <a href="#Section_1.14">(1.13)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span> <a href="#Section_1.14">(1.14)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc"><li>Dosage in patients with normal renal function <a href="#Section_2.1">(2.1)</a>
</li></ul>
<br><a name="ib6511220-5d52-463a-8efd-32d3afb4b9a2"></a><table border="0" cellpadding="0" cellspacing="0">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </th>
<th class="Lrule Rrule Toprule" align="center">Dose Every<br>24 hours</th>
<th class="Lrule Rrule Toprule" align="center">Duration <br>(days)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span> <a href="#Section_1.1">(1.1)</a><br>
</td>
<td class="Rrule" align="center" valign="top">750 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> <a href="#Section_1.2">(1.2)</a><br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> <a href="#Section_1.3">(1.3)</a><br>
</td>
<td class="Rrule" align="center" valign="top">750 mg<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="2" valign="top"> Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> <a href="#Section_1.4">(1.4)</a><br>
</td>
<td class="Rrule" align="center" valign="top">750 mg<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">10 to 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> <a href="#Section_1.5">(1.5)</a><br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (SSSI) <a href="#Section_1.6">(1.6)</a><br>
</td>
<td class="Rrule" align="center" valign="top">750 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Uncomplicated SSSI <a href="#Section_1.7">(1.7)</a><br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 10<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span> <a href="#Section_1.8">(1.8)</a><br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">28<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> <a href="#Section_1.9">(1.9)</a> or <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span> <a href="#Section_1.11">(1.11)</a><br>
</td>
<td class="Rrule" align="center" valign="top">750 mg<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> <a href="#Section_1.10">(1.10)</a> or <br> <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span> <a href="#Section_1.11">(1.11)</a><br>
</td>
<td class="Rrule" align="center" valign="top">250 mg<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> <a href="#Section_1.13">(1.12)</a><br>
</td>
<td class="Rrule" align="center" valign="top">250 mg<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure) <a href="#Section_1.14">(1.13)</a><br> Adults and Pediatric Patients &gt; 50 kg <br> Pediatric Patients &lt; 50 kg and ≥ 6 months of age <br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>8 mg/kg BID (not to exceed<br>250 mg/dose)<br>
</td>
<td class="Rrule" align="center" valign="top">60<br>60<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span> <a href="#Section_1.14">(1.14)</a><br> Adults and Pediatric Patients &gt;50 kg<br><br> Pediatric Patients &lt;50 kg and ≥ 6 months of age<br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>8 mg/kg BID<br>(not to exceed<br>250 mg/dose)<br>
</td>
<td class="Rrule" align="center" valign="top">10 to 14<br>10 to 14<br>
</td>
</tr>
</tbody>
</table>
<ul class="Disc"><li>Adjust dose for creatinine clearance &lt; 50 mL/min <a href="#Section_2.4">(2.3</a>, <a href="#Section_8.6">8.6</a>, <a href="#Section_12.3">12.3)</a>
</li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<br><a name="if75aafb2-0e7f-47ce-8a51-791f130b32b8"></a><table border="0" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold"> Formulation <a href="#Section_3">(3)</a></span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Strength </span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">   Tablets <br>
</td>
<td class="Rrule" valign="top">   250 mg, 500 mg, and 750 mg     <br>
</td>
</tr>
</tbody></table>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<br><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levofloxacin tablets or other quinolones <a href="#Section_4">(4</a>, <a href="#Section_5.3">5.3)</a> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> is increased. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroids, and in patients with kidney, heart or lung transplants. Discontinue if <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in a tendon occurs <a href="#Section_5.1">(5.1</a>, <a href="#Section_8.5">8.5)</a>
</li>
<li>May exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid use in patients with a known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <a href="#Section_5.2">(5.2)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> and <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span>, serious, occasionally fatal, may occur after first dose <a href="#Section_4">(4</a>, <a href="#Section_5.3">5.3)</a>
</li>
<li>Hematologic (including <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>), and renal toxicities may occur after multiple doses <a href="#Section_5.4">(5.4)</a>
</li>
<li>Hepatotoxicity: Severe, and sometimes fatal, hepatoxicity has been reported. Discontinue immediately if signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> occur <a href="#Section_5.5">(5.5)</a>
</li>
<li>Central nervous system effects, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> may occur after the first dose. Use with caution in patients with known or suspected disorders that may predispose them to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) has been reported <a href="#Section_5.6">(5.6)</a>
</li>
<li>
<span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>: evaluate if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs <a href="#Section_5.7">(5.7)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>: discontinue if symptoms occur in order to prevent irreversibility <a href="#Section_5.8">(5.8)</a>
</li>
<li>Prolongation of the QT interval and isolated cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> have been reported. Avoid use in patients with known prolongation, those with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and with other drugs that prolong the QT interval <a href="#Section_5.9">(5.9</a>, <a href="#Section_8.5">8.5)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta"><br>The most common reactions (≥3%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> <a href="#Section_6.2">(6.2)</a>.<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact, Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or <span class="Italics"><span class="Underline">www.fda.gov/medwatch.</span></span></span> </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<br><a name="i32ce2bf0-ef6a-44d7-803b-e9efaf1e492a"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">Interacting Drug </th>
<th class="Lrule Rrule Toprule">Interaction </th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">   Multivalent cation-containing products<br>   including antacids, metal cations or didanosine <br>
</td>
<td class="Rrule" valign="top">   Absorption of levofloxacin is decreased when the tablet<br>   formulation  is taken within 2 hours of this product. <a href="#Section_2.5">(2.4</a>, <a href="#Section_7.1">7.1)</a><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Warfarin <br>
</td>
<td class="Rrule" valign="top">   Effect may be enhanced. Monitor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time,<br>   INR, watch for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <a href="#Section_7.2">(7.2)</a><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">   Antidiabetic agents <br>
</td>
<td class="Rrule" valign="top">   Carefully monitor blood glucose <a href="#Section_5.11">(5.11</a>, <a href="#Section_7.3">7.3)</a><br>
</td>
</tr>
</tbody>
</table>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold">Geriatrics:</span> Severe hepatotoxicity has been reported. The majority of reports describe patients 65 years of age or older <a href="#Section_5.5">(5.5</a>, <a href="#Section_8.5">8.5</a>, <a href="#Section_17">17)</a>. May have increased risk of tendinopathy (including rupture), especially with concomitant corticosteroid use <a href="#Section_5.1">(5.1</a>, <a href="#Section_8.5">8.5</a>, <a href="#Section_17">17)</a>. May be more susceptible to prolongation of the QT interval <a href="#Section_5.9">(5.9</a>, <a href="#Section_8.5">8.5</a>, <a href="#Section_17">17)</a>
</li>
<li>
<span class="Bold">Pediatrics:</span> <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal disorders</span> (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, tendinopathy, and gait abnormality) seen in more levofloxacin-treated patients than in comparator. Shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> and <span class="product-label-link" type="condition" conceptid="433565" conceptname="Juvenile osteochondrosis of spine">osteochondrosis</span> in juvenile animals <a href="#Section_5.10">(5.10</a>, <a href="#Section_8.4">8.4</a>, <a href="#Section_13.2">13.2)</a>. Safety in pediatric patients treated for more than 14 days has not been studied. Risk-benefit appropriate only for the treatment of inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure) <a href="#Section_1.14">(1.13</a>, <a href="#Section_2.3">2.2</a>, <a href="#Section_8.4">8.4</a>, <a href="#Section_14.11">14.9)</a> and <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> <a href="#Section_1.14">(1.14</a>, <a href="#Section_2.3">2.2</a>, <a href="#Section_8.4">8.4</a>, <a href="#Section_14.10">14.10)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">WARNING</a></h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-2.1" class="toc">1.1 	<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span> </a></h2>
<h2><a href="#section-2.2" class="toc">1.2	Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 7 to 14 day Treatment Regimen </a></h2>
<h2><a href="#section-2.3" class="toc">1.3	Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 5-day Treatment Regimen </a></h2>
<h2><a href="#section-2.4" class="toc">1.4	Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>: 5-day and 10 to 14 day Treatment Regimens </a></h2>
<h2><a href="#section-2.5" class="toc">1.5	<span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> </a></h2>
<h2><a href="#section-2.6" class="toc">1.6	Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </a></h2>
<h2><a href="#section-2.7" class="toc">1.7	Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </a></h2>
<h2><a href="#section-2.8" class="toc">1.8	Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span> </a></h2>
<h2><a href="#section-2.9" class="toc">1.9	Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>: 5-day Treatment Regimen </a></h2>
<h2><a href="#section-2.10" class="toc">1.10	Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>: 10-day Treatment Regimen</a></h2>
<h2><a href="#section-2.11" class="toc">1.11	<span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 5 or 10-day Treatment Regimen </a></h2>
<h2><a href="#section-2.12" class="toc">1.12	Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> </a></h2>
<h2><a href="#section-2.13" class="toc">1.13	Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure) </a></h2>
<h2><a href="#section-2.14" class="toc">1.14  <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span></a></h2>
<h1><a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-3.1" class="toc">2.1 Dosage in Adult Patients with Normal Renal Function </a></h2>
<h2><a href="#section-3.2" class="toc">2.2	Dosage in Pediatric Patients</a></h2>
<h2><a href="#section-3.3" class="toc">2.3	Dosage Adjustment in Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-3.4" class="toc">2.4	Drug Interaction With Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins </a></h2>
<h2><a href="#section-3.5" class="toc">2.5	Administration Instructions </a></h2>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1	Tendinopathy and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon Rupture</span> </a></h2>
<h2><a href="#section-6.2" class="toc">5.2  Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span> </a></h2>
<h2><a href="#section-6.3" class="toc">5.3  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </a></h2>
<h2><a href="#section-6.4" class="toc">5.4  Other Serious and Sometimes Fatal Reactions </a></h2>
<h2><a href="#section-6.5" class="toc">5.5  Hepatotoxicity </a></h2>
<h2><a href="#section-6.6" class="toc">5.6  Central Nervous System Effects </a></h2>
<h2><a href="#section-6.7" class="toc">5.7  Clostridium difficile-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </a></h2>
<h2><a href="#section-6.8" class="toc">5.8  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></a></h2>
<h2><a href="#section-6.9" class="toc">5.9  Prolongation of the QT Interval </a></h2>
<h2><a href="#section-6.10" class="toc">5.10  <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span> in Pediatric Patients and Arthropathic Effects in Animals</a></h2>
<h2><a href="#section-6.11" class="toc">5.11  Blood Glucose Disturbances </a></h2>
<h2><a href="#section-6.12" class="toc">5.12  <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span> </a></h2>
<h2><a href="#section-6.13" class="toc">5.13  Development of Drug Resistant Bacteria </a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1	Serious and Otherwise Important Adverse Reactions </a></h2>
<h2><a href="#section-7.2" class="toc">6.2	Clinical Trial Experience </a></h2>
<h2><a href="#section-7.3" class="toc">6.3	Postmarketing Experience </a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-8.1" class="toc">7.1	Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins </a></h2>
<h2><a href="#section-8.2" class="toc">7.2	Warfarin </a></h2>
<h2><a href="#section-8.3" class="toc">7.3	Antidiabetic Agents </a></h2>
<h2><a href="#section-8.4" class="toc">7.4	Non-Steroidal Anti-Inflammatory Drugs </a></h2>
<h2><a href="#section-8.5" class="toc">7.5	Theophylline </a></h2>
<h2><a href="#section-8.6" class="toc">7.6	Cyclosporine</a></h2>
<h2><a href="#section-8.7" class="toc">7.7	Digoxin </a></h2>
<h2><a href="#section-8.8" class="toc">7.8	Probenecid and Cimetidine</a></h2>
<h2><a href="#section-8.9" class="toc">7.9	Interactions with Laboratory or Diagnostic Testing </a></h2>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-9.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-9.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-9.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h2><a href="#section-9.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-12.3" class="toc">12.4	Microbiology </a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2	Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1	<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span> </a></h2>
<h2><a href="#section-14.2" class="toc">14.2	Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 7 to 14 day Treatment Regimen </a></h2>
<h2><a href="#section-14.3" class="toc">14.3	Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 5-day Treatment Regimen </a></h2>
<h2><a href="#section-14.4" class="toc">14.4	Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>: 5-day and 10 to 14 day Treatment Regimens </a></h2>
<h2><a href="#section-14.5" class="toc">14.5 	Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </a></h2>
<h2><a href="#section-14.6" class="toc">14.6 	Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span> </a></h2>
<h2><a href="#section-14.7" class="toc">14.7	Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 5-day Treatment Regimen </a></h2>
<h2><a href="#section-14.8" class="toc">14.8	Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 10-day Treatment Regimen</a></h2>
<h2><a href="#section-14.9" class="toc">14.9	Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure) </a></h2>
<h2><a href="#section-14.10" class="toc">14.10  <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span></a></h2>
<h1><a href="#section-15" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-16" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-16.1" class="toc">16.1	Levofloxacin Tablets</a></h2>
<h1><a href="#section-17" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-17.1" class="toc">17.1	Antibacterial Resistance </a></h2>
<h2><a href="#section-17.2" class="toc">17.2	Administration with Food, Fluids, and Concomitant Medications</a></h2>
<h2><a href="#section-17.3" class="toc">17.3	Serious and Potentially Serious Adverse Reactions </a></h2>
<h2><a href="#section-17.4" class="toc">17.4	Drug Interactions with Insulin, Oral Hypoglycemic Agents, and Warfarin</a></h2>
<h2><a href="#section-17.5" class="toc">17.5  <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span> and <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> Studies</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="Section_29"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Section_0"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First"><br><span class="Bold">Fluoroquinolones, including levofloxacin, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.<br><br><span class="Bold">Fluoroquinolones, including levofloxacin, may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid levofloxacin in patients with a known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span></span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"><br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets <span class="Sup"></span>and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.<br><br>Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Levofloxacin <span class="Sup"></span>injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form).<span class="Bold"><br><br>Culture and susceptibility testing</span><br><br>Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and to determine their susceptibility to levofloxacin <span class="Italics">[see <a href="#Section_12.4">Clinical Pharmacology (12.4)</a>]</span>. Therapy with levofloxacin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.<br><br>As with other drugs in this class, some isolates of <span class="Italics">Pseudomonas aeruginosa</span> may develop resistance fairly rapidly during treatment with levofloxacin tablets. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">bacterial resistance</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.1"></a><a name="section-2.1"></a><p></p>
<h2>1.1 	<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span> </h2>
<p class="First"><br>Levofloxacin tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> due to methicillin-susceptible <span class="Italics">Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae,</span> or <span class="Italics">Streptococcus pneumoniae</span>. Adjunctive therapy should be used as clinically indicated. Where <span class="Italics">Pseudomonas aeruginosa</span> is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal ⛚-lactam is recommended <span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.2"></a><a name="section-2.2"></a><p></p>
<h2>1.2	Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 7 to 14 day Treatment Regimen </h2>
<p class="First"><br>Levofloxacin tablets are indicated for the treatment of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> due to methicillin-susceptible<span class="Italics"> Staphylococcus aureus, Streptococcus pneumoniae</span> (including multi-drug-resistant <span class="Italics">Streptococcus pneumoniae</span> [MDRSP]), <span class="Italics">Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, </span>or<span class="Italics"> Mycoplasma pneumoniae [see <a href="#Section_2.1">Dosage and Administration (2.1)</a> and <a href="#Section_14.4">Clinical Studies (14.2)</a>]</span>.<br><br>MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2<span class="Sup">nd</span> generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.3"></a><a name="section-2.3"></a><p></p>
<h2>1.3	Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 5-day Treatment Regimen </h2>
<br><p class="First">Levofloxacin tablets are indicated for the treatment of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> due to <span class="Italics">Streptococcus pneumoniae</span> (excluding multi-drug-resistant isolates [MDRSP]), <span class="Italics">Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see <a href="#Section_2.1">Dosage and Administration (2.1)</a> and <a href="#Section_14.5">Clinical Studies (14.3)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.4"></a><a name="section-2.4"></a><p></p>
<h2>1.4	Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>: 5-day and 10 to 14 day Treatment Regimens </h2>
<br><p class="First">Levofloxacin tablets are indicated for the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> due to <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Haemophilus influenzae, </span>or<span class="Italics"> Moraxella catarrhalis [see <a href="#Section_14.6">Clinical Studies (14.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.5"></a><a name="section-2.5"></a><p></p>
<h2>1.5	<span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> </h2>
<br><p class="First">Levofloxacin tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">acute bacterial exacerbation of chronic bronchitis</span> due to methicillin-susceptible <span class="Italics">Staphylococcus aureus</span>, <span class="Italics">Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, </span>or <span class="Italics">Moraxella catarrhalis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.6"></a><a name="section-2.6"></a><p></p>
<h2>1.6	Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </h2>
<br><p class="First">Levofloxacin tablets are indicated for the treatment of complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to methicillin-susceptible <span class="Italics">Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, </span>or<span class="Italics"> Proteus mirabilis [see <a href="#Section_14.7">Clinical Studies (14.5)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.7"></a><a name="section-2.7"></a><p></p>
<h2>1.7	Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </h2>
<p class="First"><br>Levofloxacin tablets are indicated for the treatment of uncomplicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (mild to moderate) including <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furuncles</span>, <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span>, <span class="product-label-link" type="condition" conceptid="133547" conceptname="Pyoderma">pyoderma</span>, <span class="product-label-link" type="condition" conceptid="4153877" conceptname="Post-traumatic wound infection">wound infections</span>, due to methicillin-susceptible<span class="Italics"> Staphylococcus aureus</span>, or <span class="Italics">Streptococcus pyogenes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.8"></a><a name="section-2.8"></a><p></p>
<h2>1.8	Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span> </h2>
<p class="First"><br>Levofloxacin tablets are indicated for the treatment of chronic bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span> due to <span class="Italics">Escherichia coli, Enterococcus faecalis, </span>or methicillin-susceptible<span class="Italics"> Staphylococcus epidermidis [see <a href="#Section_14.8">Clinical Studies (14.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.9"></a><a name="section-2.9"></a><p></p>
<h2>1.9	Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>: 5-day Treatment Regimen </h2>
<br><p class="First">Levofloxacin tablets are indicated for the treatment of complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> due to <span class="Italics">Escherichia coli, Klebsiella pneumoniae, </span>or <span class="Italics">Proteus mirabilis [see <a href="#Section_14.9">Clinical Studies (14.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.10"></a><a name="section-2.10"></a><p></p>
<h2>1.10	Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>: 10-day Treatment Regimen</h2>
<p class="First"><br>Levofloxacin tablets are indicated for the treatment of complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (mild to moderate) due to <span class="Italics">Enterococcus faecalis</span>, <span class="Italics">Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis,</span> or <span class="Italics">Pseudomonas aeruginosa [see <a href="#Section_14.10">Clinical Studies (14.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.11"></a><a name="section-2.11"></a><p></p>
<h2>1.11	<span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 5 or 10-day Treatment Regimen </h2>
<br><p class="First">Levofloxacin tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">acute pyelonephritis</span> caused by <span class="Italics">Escherichia coli</span>, including cases with concurrent <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> <span class="Italics">[see <a href="#Section_14.9">Clinical Studies (14.7</a>, <a href="#Section_14.10">14.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.13"></a><a name="section-2.12"></a><p></p>
<h2>1.12	Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> </h2>
<br><p class="First">Levofloxacin tablets are indicated for the treatment of uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (mild to moderate) due to <span class="Italics">Escherichia coli, Klebsiella pneumoniae, </span>or<span class="Italics"> Staphylococcus saprophyticus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.14"></a><a name="section-2.13"></a><p></p>
<h2>1.13	Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure) </h2>
<br><p class="First">Levofloxacin tablets are indicated for inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized <span class="Italics">Bacillus anthracis. </span>The effectiveness of levofloxacin tablets is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin tablets have not been tested in humans for the post-exposure prevention of inhalation <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>. The safety of levofloxacin tablets in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin tablets therapy should only be used when the benefit outweighs the risk <span class="Italics">[see <a href="#Section_2.1">Dosage and Administration (2.1</a>, <a href="#Section_2.3">2.2)</a> and <a href="#Section_14.11">Clinical Studies (14.9)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.18"></a><a name="section-2.14"></a><p></p>
<h2>1.14  <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span></h2>
<p class="First" style="border-left:1px solid;"><br>Levofloxacin tablets <span class="Sup"></span><span class="XmChange">are</span> indicated for treatment of <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span>, including pneumonic and septicemic <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span>, due to <span class="Italics">Yersinia pestis </span>(<span class="Italics">Y. pestis</span>) and prophylaxis for <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> in adults and pediatric patients, 6 months of age <span class="XmChange">and</span> older. Efficacy studies of levofloxacin tablets could not be conducted in humans with <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals <span class="Italics">[see <a href="#Section_2.1">Dosage and Administration (2.1</a>, <a href="#Section_2.3">2.2)</a> and <a href="#Section_14.16">Clinical Studies (14.10)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-3"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-3.1"></a><p></p>
<h2>2.1 Dosage in Adult Patients with Normal Renal Function </h2>
<p class="First"><br>The usual dose of levofloxacin tablets is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and described in Table 1.<br><br>These recommendations apply to patients with creatinine clearance ≥ 50 mL/min. For patients with creatinine clearance &lt;50 mL/min, adjustments to the dosing regimen are required <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.3)</a>]</span>.<br></p>
<a name="i98c4185b-767d-4be8-8b9b-361c48a51eef"></a><table border="0" cellpadding="0" cellspacing="0" width="601">
<caption><span>Table 1: Dosage in Adult Patients with Normal Renal Function (creatinine clearance ≥ 50 mL/min) 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><span class="Sup">1</span>
</th>
<th class="Lrule Rrule Toprule" align="center">Dosed Every 24 hours</th>
<th class="Lrule Rrule Toprule" align="center">Duration (days)<span class="Sup">2</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">1 </span>Due to the designated pathogens <span class="Italics">[see <a href="#Section_1">Indications and Usage (1)</a>]</span>.<br><span class="Sup">2 </span>Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician.<br><span class="Sup">3 </span>Due to methicillin-susceptible<span class="Italics"> Staphylococcus aureus, Streptococcus pneumoniae </span>(including multi-drug-resistant isolates [MDRSP]), <span class="Italics">Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, </span>or <span class="Italics">Mycoplasma pneumoniae [see <a href="#Section_1.2">Indications and Usage (1.2)</a>].</span><br><span class="Sup">4 </span>Due to<span class="Italics"> Streptococcus pneumoniae </span>(excluding multi-drug-resistant isolates [MDRSP]), <span class="Italics">Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see <a href="#Section_1.3">Indications and Usage (1.3)</a>].</span><br><span class="Sup">5 </span>This regimen is indicated for cUTI due to <span class="Italics">Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis </span>and AP due to <span class="Italics">E. coli,</span> including cases with concurrent <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>.<br><span class="Sup">6 </span>This regimen is indicated for cUTI due to<span class="Italics"> Enterococcus faecalis, Enterococcus cloacae, Escherichia coli</span>, <span class="Italics">Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa</span>; and for AP due to<span class="Italics"> E. coli.</span><br><span class="Sup">7 </span>Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized <span class="Italics">B. anthracis</span>. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit <span class="Italics">[see <a href="#Section_14.11">Clinical Studies (14.9)</a>]</span>.<br><span class="Sup">8 </span>The safety of levofloxacin tablets in adults for durations of therapy beyond 28 days or in pediatric patients for durations beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.10)</a>, <a href="#Section_8.4">Use in Specific Populations (8.4)</a>, and <a href="#Section_14.11">Clinical Studies (14.9)</a>]</span>. Prolonged levofloxacin tablets therapy should only be used when the benefit outweighs the risk.<br><span class="Sup">9</span> Drug administration should begin <span class="XmChange"><span class="XmChange"><span class="XmChange">as</span></span></span> soon as possible after suspected or confirmed exposure to <span class="Italics">Yersinia pestis</span>. Higher doses of levofloxacin tablets typically used for treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> can be used for treatment of <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span>, if clinically indicated.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">750 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span><span class="Sup">3</span><br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span><span class="Sup">4 </span><br>
</td>
<td class="Rrule" align="center" valign="top">750 mg<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="2" valign="top"> Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">750 mg<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">10 to 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (SSSI) <br>
</td>
<td class="Rrule" align="center" valign="top">750 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Uncomplicated SSSI <br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 10<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">28<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> (cUTI) or <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span> (AP)<span class="Sup">5</span><br>
</td>
<td class="Rrule" align="center" valign="top">750 mg<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> (cUTI) or <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span> (AP)<span class="Sup">6</span><br>
</td>
<td class="Rrule" align="center" valign="top">250 mg<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> <br>
</td>
<td class="Rrule" align="center" valign="top">250 mg<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure), adult and pediatric patients &gt; 50 kg<span class="Sup">7,8</span><br> Pediatric patients &lt; 50 kg and ≥ 6 months of age <span class="Sup">7,8</span><br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br><br>see Table 2 below (2.2)<br>
</td>
<td class="Rrule" align="center" valign="top">60<span class="Sup">8</span><br>60<span class="Sup">8</span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span>, adult <span class="XmChange"><span class="XmChange"><span class="XmChange">and</span></span></span> pediatric patients &gt; 50 kg<span class="Sup">9</span><br> Pediatric patients &lt; 50 kg and ≥ 6 months of age <br>
</td>
<td class="Rrule" align="center" valign="top">500 mg <br>see Table 2 below (2.2) <br>
</td>
<td class="Rrule" align="center" valign="top">10 to 14 <br>10 to 14 <br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-3.2"></a><p></p>
<h2>2.2	Dosage in Pediatric Patients</h2>
<p class="First"><br>The dosage in pediatric patients ≥ 6 months of age is described below in Table 2.<br><br></p>
<a name="i45a5d39a-852a-4ec4-8389-89ac222c209f"></a><table border="0" cellpadding="0" cellspacing="0" width="588">
<caption><span>Table 2: Dosage in Pediatric Patients ≥ 6 months of age  
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><span class="Sup">1</span>
</th>
<th class="Lrule Rrule Toprule" align="center">Dose</th>
<th class="Lrule Rrule Toprule" align="center">Freq. Once<br>every</th>
<th class="Lrule Rrule Toprule" align="center">Duration<span class="Sup">2</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="4">
<span class="Sup">1</span> Due to <span class="Italics">Bacillus anthracis [see <a href="#Section_1.14">Indications and Usage (1.13)</a>]</span> and <span class="Italics">Yersinia pestis [see <a href="#Section_1.14">Indications and Usage (1.14)</a>]</span>.<span class="Italics"></span><br><span class="Sup">2</span> Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician.<br><span class="Sup">3</span> Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized <span class="Italics">B. anthracis</span>. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit <span class="Italics">[see <a href="#Section_14.11">Clinical Studies (14.9)</a>].</span><br><span class="Sup">4</span> The safety of levofloxacin tablets in pediatric patients for durations of therapy beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.10)</a>, <a href="#Section_8.4">Use in Specific Populations (8.4)</a>, and <a href="#Section_14.11">Clinical Studies (14.9)</a>]</span>. Prolonged levofloxacin tablets therapy should only be used when the benefit outweighs the risk. <br><span class="Sup">5</span> Drug administration should begin <span class="XmChange"><span class="XmChange"><span class="XmChange">as</span></span></span> soon as possible after suspected or confirmed exposure to <span class="Italics">Yersinia pestis</span>.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" colspan="4" valign="top"> Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (post-exposure)<span class="Sup">3, 4</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">     Pediatric patients &gt; 50 kg <br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">24 hr<br>
</td>
<td class="Rrule" align="center" valign="top">60 days<span class="Sup">4</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">     Pediatric patients &lt; 50 kg and ≥ 6 months of age<br>
</td>
<td class="Rrule" align="center" valign="top">8 mg/kg <br>(not to exceed <br>250 mg per dose)<br>
</td>
<td class="Rrule" align="center" valign="top">12 hr<br>
</td>
<td class="Rrule" align="center" valign="top">60 days<span class="Sup">4</span><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="4" valign="top">
<span class="XmChange"><span class="XmChange"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span></span></span><span class="Sup">5</span></span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">     Pediatric patients &gt; 50 <span class="XmChange"><span class="XmChange"><span class="XmChange">kg</span></span></span><br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">24 hr<br>
</td>
<td class="Rrule" align="center" valign="top">10 to 14 days<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">     Pediatric patients &lt; 50 <span class="XmChange">kg</span> and ≥ 6 months <span class="XmChange">of</span> age<br>
</td>
<td class="Rrule" align="center" valign="top">8 mg/kg <br>(not to exceed <br>250 mg per dose)<br>
</td>
<td class="Rrule" align="center" valign="top">12 hr<br>
</td>
<td class="Rrule" align="center" valign="top">10 to 14 days<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-3.3"></a><p></p>
<h2>2.3	Dosage Adjustment in Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><br>Administer levofloxacin tablets with caution in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced.<br><br>No adjustment is necessary for patients with a creatinine clearance ≥ 50 mL/min.<br><br>In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance &lt;50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance <span class="Italics">[see <a href="#Section_8.6">Use in Specific Populations (8.6)</a>]</span>.<br><br>Table 3 shows how to adjust dose based on creatinine clearance.<br></p>
<a name="id0440e99-e506-4d8e-8741-e20f57dff5d7"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 3: Dosage Adjustment in Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (creatinine clearance &lt;50 mL/min) 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Dosage in<br>Normal Renal<br>Function Every<br>24 hours</th>
<th class="Lrule Rrule Toprule" align="center">Creatinine<br>Clearance<br>20 to 49 mL/min</th>
<th class="Lrule Rrule Toprule" align="center">Creatinine<br>Clearance<br>10 to 19 mL/min</th>
<th class="Lrule Rrule Toprule" align="center">Hemodialysis or<br>Chronic Ambulatory<br>Peritoneal Dialysis<br>(CAPD)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">   750 mg<br>
</td>
<td class="Rrule" valign="top">   750 mg every 48 hours<br>
</td>
<td class="Rrule" valign="top">   750 mg initial dose, then<br>   500 mg every 48 hours<br>
</td>
<td class="Rrule" valign="top">   750 mg initial dose, then <br>   500 mg every 48 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   500 mg<br>
</td>
<td class="Rrule" valign="top">   500 mg initial dose, then <br>   250 mg every 24 hours<br>
</td>
<td class="Rrule" valign="top">   500 mg initial dose, then<br>   250 mg every 48 hours<br>
</td>
<td class="Rrule" valign="top">   500 mg initial dose, then <br>   250 mg every 48 hours<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">   250 mg<br>
</td>
<td class="Rrule" valign="top">   No dosage adjustment <br>   required<br>
</td>
<td class="Rrule" valign="top">   250 mg every 48 hours. <br>   If treating uncomplicated <br>   UTI, then no dosage <br>   adjustment is required<br>
</td>
<td class="Rrule" valign="top">   No information on <br>   dosing adjustment is available<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.5"></a><a name="section-3.4"></a><p></p>
<h2>2.4	Drug Interaction With Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins </h2>
<br><p class="First">Levofloxacin tablets should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine chewable/buffered tablets or the pediatric powder for oral solution <span class="Italics">[see <a href="#Section_7.1">Drug Interactions (7.1)</a> and <a href="#Section_17.2">Patient Counseling Information (17.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.6"></a><a name="section-3.5"></a><p></p>
<h2>2.5	Administration Instructions </h2>
<p class="First"><br><span class="Bold">Food and Levofloxacin Tablets</span><br><br>Levofloxacin tablets can be administered without regard to food.<br><span class="Bold"><br>Hydration for Patients Receiving Levofloxacin Tablets</span><br><br>Adequate hydration of patients receiving oral levofloxacin tablets should be maintained to prevent the formation of highly concentrated urine. <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> and <span class="product-label-link" type="condition" conceptid="442282" conceptname="Urinary casts">cylindruria</span> have been reported with quinolones <span class="Italics">[see <a href="#Section_6.1">Adverse Reactions (6.1)</a></span><span class="Italics">and </span><span class="Italics"><a href="#Section_17.2">Patient Counseling Information (17.2)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-4"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><br>Levofloxacin tablets, 250 mg are terra pink colored capsule shaped, biconvex film-coated tablets, debossed with ‘13’ on one side and ‘T’ on the other side.<br><br>Levofloxacin tablets, 500 mg are peach colored capsule shaped, biconvex film-coated tablets, debossed with ‘12’ on one side and ‘T’ on the other side.<br><br>Levofloxacin tablets, 750 mg are white capsule shaped, biconvex film-coated tablets, debossed with ‘11’ on one side and ‘T’ on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<br><p class="First">Levofloxacin tablets are contraindicated in persons with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levofloxacin, or other quinolone antibacterials <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-6.1"></a><p></p>
<h2>5.1	Tendinopathy and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon Rupture</span> </h2>
<br><p class="First">Fluoroquinolones, including levofloxacin, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. This adverse reaction most frequently involves the Achilles tendon, and rupture of the Achilles tendon may require surgical repair. <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites have also been reported. The risk of developing fluoroquinolone-associated <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> is further increased in older patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Factors, in addition to age and corticosteroid use, that may independently increase the risk of <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> include strenuous physical activity, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and previous <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> such as <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> have been reported in patients taking fluoroquinolones who do not have the above risk factors. <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> can occur during or after completion of therapy; cases occurring up to several months after completion of therapy have been reported. Levofloxacin should be discontinued if the patient experiences <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or rupture of a tendon. Patients should be advised to rest at the first sign of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug <span class="Italics">[see <a href="#Section_6.3">Adverse Reactions (6.3)</a>; <a href="#Section_17.3">Patient Counseling Information (17.3)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-6.2"></a><p></p>
<h2>5.2  Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span> </h2>
<p class="First"><br>Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Postmarketing serious adverse events, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and requirement for ventilatory support, have been associated with fluoroquinolone use in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid levofloxacin in patients with a known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">[see </span><span class="Italics"><a href="#Section_6.3">Adverse Reactions (6.3)</a>; <a href="#Section_17.3">Patient Counseling Information (17.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-6.3"></a><p></p>
<h2>5.3  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </h2>
<br><p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and/or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> have been reported in patients receiving therapy with fluoroquinolones, including levofloxacin. These reactions often occur following the first dose. Some reactions have been accompanied by <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including tongue, laryngeal, throat, or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>), airway obstruction (including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and acute <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and other serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. Levofloxacin should be discontinued immediately at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. Serious acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated<span class="Italics"> [see <a href="#Section_6">Adverse Reactions (6)</a>; <a href="#Section_17.3">Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-6.4"></a><p></p>
<h2>5.4  Other Serious and Sometimes Fatal Reactions </h2>
<p class="First"><br>Other serious and sometimes fatal events, some due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, and some due to uncertain etiology, have been reported rarely in patients receiving therapy with fluoroquinolones, including levofloxacin. These events may be severe and generally occur following the administration of multiple doses. Clinical manifestations may include one or more of the following:<br></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or severe dermatologic reactions (e.g., <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>); </li>
<li><span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>; </li>
<li>allergic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>; </li>
<li>interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>; <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal insufficiency</span> or failure; </li>
<li><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>; <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>; acute <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> or failure; </li>
<li><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, including hemolytic and aplastic; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, including <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>; <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>; and/or other hematologic abnormalities.</li>
</ul>
<p>The drug should be discontinued immediately at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and supportive measures instituted <span class="Italics">[see <a href="#Section_6">Adverse Reactions (6)</a>; <a href="#Section_17.3">Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-6.5"></a><p></p>
<h2>5.5  Hepatotoxicity </h2>
<br><p class="First">Postmarketing reports of severe hepatotoxicity (including acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and fatal events) have been received for patients treated with levofloxacin. No evidence of serious drug-associated hepatotoxicity was detected in clinical trials of over 7,000 patients. Severe hepatotoxicity generally occurred within 14 days of initiation of therapy and most cases occurred within 6 days. Most cases of severe hepatotoxicity were not associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>]</span>. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. Levofloxacin should be discontinued immediately if the patient develops signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> <span class="Italics">[see <a href="#Section_6">Adverse Reactions (6)</a>; <a href="#Section_17.3">Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-6.6"></a><p></p>
<h2>5.6  Central Nervous System Effects </h2>
<p class="First" style="border-left:1px solid;"><br><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="XmChange">toxic</span> psychoses, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> (including <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) have been reported in patients receiving fluoroquinolones, including levofloxacin. Fluoroquinolones may also cause central nervous system stimulation which may lead to <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and, rarely, suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving levofloxacin, the drug should be discontinued and appropriate measures instituted. As with other fluoroquinolones, levofloxacin should be used with caution in patients with a known or suspected central nervous system (CNS) disorder that may predispose them to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold (e.g., severe <span class="product-label-link" type="condition" conceptid="4278243" conceptname="Cerebral arteriosclerosis">cerebral arteriosclerosis</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>) or in the presence of other risk factors that may predispose them to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold (e.g., certain drug therapy, renal dysfunction.) <span class="Italics">[see <a href="#Section_6">Adverse Reactions (6)</a></span>; <span class="Italics"><a href="#Section_7.5">Drug Interactions (7.4</a>, <a href="#Section_7.6">7.5)</a></span>; <span class="Italics"><a href="#Section_17.3">Patient Counseling Information (17.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-6.7"></a><p></p>
<h2>5.7  Clostridium difficile-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </h2>
<p class="First"><br><span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including levofloxacin, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.<span class="Italics"><br><br>C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. <br><br>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile,</span> and surgical evaluation should be instituted as clinically indicated <span class="Italics">[see <a href="#Section_6.2">Adverse Reactions (6.2)</a>, <a href="#Section_17.3">Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.8"></a><a name="section-6.8"></a><p></p>
<h2>5.8  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></h2>
<br><p class="First">Rare cases of sensory or sensorimotor axonal <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> affecting small and/or large axons resulting in <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesias</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesias</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> have been reported in patients receiving fluoroquinolones, including levofloxacin. Levofloxacin should be discontinued if the patient experiences symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and/or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or other alterations of sensation including light touch, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, temperature, position sense, and vibratory sensation in order to prevent the development of an irreversible condition <span class="Italics">[see <a href="#Section_6">Adverse Reactions (6)</a>, <a href="#Section_17.3">Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.9"></a><a name="section-6.9"></a><p></p>
<h2>5.9  Prolongation of the QT Interval </h2>
<br><p class="First">Some fluoroquinolones, including levofloxacin, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Rare cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> have been spontaneously reported during postmarketing surveillance in patients receiving fluoroquinolones, including levofloxacin. Levofloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval <span class="Italics">[see <a href="#Section_6.3">Adverse Reactions (6.3)</a>, <a href="#Section_8.5">Use in Specific Populations (8.5)</a>, and <a href="#Section_17.3">Patient Counseling Information (17.3)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.10"></a><a name="section-6.10"></a><p></p>
<h2>5.10  <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span> in Pediatric Patients and Arthropathic Effects in Animals</h2>
<p class="First" style="border-left:1px solid;"><br>Levofloxacin <span class="Sup"></span>is indicated <span class="XmChange" style="border-left:1px solid;"><span class="XmChange" style="border-left:1px solid;"><span class="XmChange">in</span></span></span> pediatric patients (6 months of age and older) only for the prevention of inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure) and for <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> <span class="Italics">[see <a href="#Section_1.14">Indications and Usage (1.13</a>, <a href="#Section_1.14">1.14)</a>]</span>. An increased incidence of <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, tendinopathy, and gait abnormality) compared to controls has been observed in pediatric patients receiving levofloxacin<span class="Sup"></span><span class="Italics"> [see Use in <a href="#Section_8.4">Specific Populations (8.4)</a>]</span>.<br><br>In immature rats and dogs, the oral administration of levofloxacin resulted in increased <span class="product-label-link" type="condition" conceptid="433565" conceptname="Juvenile osteochondrosis of spine">osteochondrosis</span>. Histopathological examination of the weight-bearing joints of immature dogs dosed with levofloxacin revealed persistent lesions of the cartilage. Other fluoroquinolones also produce similar erosions in the weight-bearing joints and other signs of <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of various species <span class="Italics">[see <a href="#Section_13.2">Animal Toxicology and/or Pharmacology (13.2)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.11"></a><a name="section-6.11"></a><p></p>
<h2>5.11  Blood Glucose Disturbances </h2>
<br><p class="First">As with other fluoroquinolones, disturbances of blood glucose, including symptomatic hyper- and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, have been reported with levofloxacin, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended. If a <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reaction</span> occurs in a patient being treated with levofloxacin, levofloxacin should be discontinued and appropriate therapy should be initiated immediately <span class="Italics">[see <a href="#Section_6.2">Adverse Reactions (6.2)</a>; <a href="#Section_7.3">Drug Interactions (7.3)</a>; <a href="#Section_17.4">Patient Counseling Information (17.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.12"></a><a name="section-6.12"></a><p></p>
<h2>5.12  <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span> </h2>
<p class="First"><br>Moderate to severe <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, exudation, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) involving areas exposed to light (typically the face, “V? area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of fluoroquinolones after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> occurs <span class="Italics">[see <a href="#Section_6.3">Adverse Reactions (6.3)</a>; <a href="#Section_17.3">Patient Counseling Information (17.3)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.13"></a><a name="section-6.13"></a><p></p>
<h2>5.13  Development of Drug Resistant Bacteria </h2>
<p class="First"><br>Prescribing levofloxacin in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria <span class="Italics">[see <a href="#Section_17.1">Patient Counseling Information (17.1)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-7.1"></a><p></p>
<h2>6.1	Serious and Otherwise Important Adverse Reactions </h2>
<p class="First"><br>The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:<br></p>
<ul class="Disc">
<li>Tendon Effects <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span> <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>] </span>
</li>
<li>Other Serious and Sometimes Fatal Reactions <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>] </span>
</li>
<li>Hepatotoxicity <span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>] </span>
</li>
<li>Central Nervous System Effects <span class="Italics">[see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>] </span>
</li>
<li>
<span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> <span class="Italics">[see <a href="#Section_5.7">Warnings and Precautions (5.7)</a>] </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span> <span class="Italics">[see <a href="#Section_5.8">Warnings and Precautions (5.8)</a>] </span>
</li>
<li>Prolongation of the QT Interval <span class="Italics">[see <a href="#Section_5.9">Warnings and Precautions (5.9)</a>] </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span> in Pediatric Patients <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.10)</a>] </span>
</li>
<li>Blood Glucose Disturbances <span class="Italics">[see <a href="#Section_5.11">Warnings and Precautions (5.11)</a>] </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span> <span class="Italics">[see <a href="#Section_5.12">Warnings and Precautions (5.12)</a>]</span>
</li>
<li>Development of Drug Resistant Bacteria <span class="Italics">[see <a href="#Section_5.13">Warnings and Precautions (5.13)</a>] </span>
</li>
</ul>
<p><br><span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> and <span class="product-label-link" type="condition" conceptid="442282" conceptname="Urinary casts">cylindruria</span> have been reported with quinolones, including levofloxacin. Therefore, adequate hydration of patients receiving levofloxacin should be maintained to prevent the formation of a highly concentrated urine <span class="Italics">[see <a href="#Section_2.6">Dosage and Administration (2.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-7.2"></a><p></p>
<h2>6.2	Clinical Trial Experience </h2>
<p class="First"><br>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br><br>The data described below reflect exposure to levofloxacin in 7537 patients in 29 pooled Phase 3 clinical trials. The population studied had a mean age of 50 years (approximately 74% of the population was &lt; 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. Patients were treated with levofloxacin for a wide variety of infectious diseases <span class="Italics">[see <a href="#Section_1">Indications and Usage (1)</a>]</span>. Patients received levofloxacin doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily. Treatment duration was usually 3 to 14 days, and the mean number of days on therapy was 10 days.<br><br>The overall incidence, type and distribution of adverse reactions was similar in patients receiving levofloxacin doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily. Discontinuation of levofloxacin due to adverse drug reactions occurred in 4.3% of patients overall, 3.8% of patients treated with the 250 mg and 500 mg doses and 5.4% of patients treated with the 750 mg dose. The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1.4%), primarily <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.6%); <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.4%); <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.3%); and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.2%). The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1.2%), primarily <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.6%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.5%); <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.3%); and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.3%).<br><br>Adverse reactions occurring in ≥1% of levofloxacin-treated patients and less common adverse reactions, occurring in 0.1 to &lt;1% of levofloxacin-treated patients, are shown in Table 4 and Table 5, respectively. The most common adverse drug reactions (≥3%) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<a name="ia7c3dfb2-8283-4a26-8d55-1c6c0b9fba8b"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 4: Common (≥1%) Adverse Reactions Reported in Clinical Trials with Levofloxacin 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">System/Organ Class </th>
<th class="Lrule Rrule Toprule">Adverse Reaction </th>
<th class="Lrule Rrule Toprule" align="center">%<br>(N = 7537) </th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">a </span>N = 7274<br><span class="Sup">b </span>N = 3758 (women) <br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Psychiatric Disorders </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span><span class="Sup">a</span><br><span class="Italics">   [see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>] </span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span><br>   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span><br><span class="Italics">   [see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>] </span><br>
</td>
<td class="Rrule" align="center" valign="top">6<br>3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Respiratory, Thoracic and </span><span class="Bold"><br><span class="Bold">   <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span> </span></span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span><br><span class="Italics">   [see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>] </span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span><br>   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><br>   <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span><br>   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span><br>   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br>   <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">7<br>5<br>3<br>2<br>2<br>2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Skin and Subcutaneous </span><span class="Bold"><br><span class="Bold">   Tissue Disorders </span></span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>] </span><span class="Italics"><br></span>   <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> <br>
</td>
<td class="Rrule" align="center" valign="top">2<br>1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Reproductive System and </span><span class="Bold"><br><span class="Bold">   <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span> </span></span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1<span class="Sup">b</span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   General Disorders and </span><span class="Bold"><br><span class="Bold">   Administration Site Conditions </span></span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span><br>   <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span><br>   <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>1<br>1<br>
</td>
</tr>
</tbody>
</table>
<br><a name="i4d968022-b0a1-4782-8cf8-8ade98a58372"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 5: Less Common (0.1 to 1%) Adverse Reactions Reported in Clinical Trials with Levofloxacin (N = 7537) 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">System/Organ Class </th>
<th class="Lrule Rrule Toprule">Adverse Reaction </th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="2">
<span class="Sup">a </span>N = 7274<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span> </span><br>
</td>
<td class="Rrule" valign="top">   genital <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Blood and Lymphatic System Disorders </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span><br>   <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> <br>   <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> <br><span class="Italics">   [see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>] </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span><br><span class="Italics">   [see <a href="#Section_5.3">Warnings and Precautions (5.3</a>, <a href="#Section_5.4">5.4)</a>] </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Metabolism and Nutrition Disorders </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> <br>   <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> <br><span class="Italics">   [see <a href="#Section_5.11">Warnings and Precautions (5.11)</a>]</span><br>   <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Psychiatric Disorders </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span><br>   <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span><br>   <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span><br>   <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span><br>   <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span><br>   <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmare</span><span class="Sup">a</span><br><span class="Italics">   [see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>]</span><br>   <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span><span class="Sup">a</span><br>   <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span><br>   abnormal dreaming<span class="Sup">a</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span><br>   <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span><br><span class="Italics">   [see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>] </span><br>   paresthesia <span class="Italics"></span><span class="Italics"><br><span class="Italics">   [see <a href="#Section_5.8">Warnings and Precautions (5.8)</a>]</span></span><br>   <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span><br>   <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span><br>   <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesias</span><br>   <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span><br>   <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span><span class="Sup">a</span><br>   <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span><br>   <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span><br>   <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span><br>   <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span><br>   <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span><br>   <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span><br>   <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span><br>   <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span><br>   <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span><br>   pseudomembranous/<span class="Italics">C. difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span><br><span class="Italics">   [see <a href="#Section_5.7">Warnings and Precautions (5.7)</a>] </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Hepatobiliary Disorders </span><br>
</td>
<td class="Rrule" valign="top">   abnormal hepatic function<br>   increased hepatic enzymes<br>   increased alkaline phosphatase <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Skin and Subcutaneous Tissue Disorders </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>] </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span><br>   <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span><br><span class="Italics">   [see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span><br><span class="Italics"></span>   <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span><br>   <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span> <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Renal and Urinary Disorders </span><br>
</td>
<td class="Rrule" valign="top">   abnormal renal function<br>   <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>] </span><br>
</td>
</tr>
</tbody>
</table>
<p> clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> and multiple punctate <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lenticular opacities</span>, have been noted in patients undergoing treatment with quinolones, including levofloxacin. The relationship of the drugs to these events is not presently established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.3"></a><a name="section-7.3"></a><p></p>
<h2>6.3	Postmarketing Experience </h2>
<p class="First"><br>Table 6 lists adverse reactions that have been identified during post-approval use of levofloxacin. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible. <br><br></p>
<a name="id52cf1eb-168f-45a4-8513-250835cf278b"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 6: Postmarketing Reports Of Adverse Drug Reactions 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">System/Organ Class </th>
<th class="Lrule Rrule Toprule">Adverse Reaction </th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Blood and Lymphatic System Disorders </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span><br>   <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span><br>   <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span><br>   <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span><br><span class="Italics">   [see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>] </span><br>   <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, sometimes fatal including:<br>      anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span><br>      anaphylactic shock <br>      <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span><br>      <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span><br><span class="Italics">   [see <a href="#Section_5.3">Warnings and Precautions (5.3</a>, <a href="#Section_5.4">5.4)</a>] </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Psychiatric Disorders </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span><br>   <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span><br>   isolated reports of <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> and suicidal ideation <span class="Italics"></span><span class="Italics"><br><span class="Italics">   [see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>] </span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span><br>   <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">anosmia</span><br>   <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">ageusia</span><br>   <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span><br>   <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span><br>   <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> <span class="Italics">[see <a href="#Section_5.8">Warnings and Precautions (5.8)</a>]</span><br>   isolated reports of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span><br>   <span class="product-label-link" type="condition" conceptid="4168553" conceptname="Electroencephalogram abnormal">abnormal electroencephalogram</span> (EEG)<br><br>   <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span> <br>   <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> <span class="Italics">[see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>]</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   vision disturbance, including <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span><br>   <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity reduced</span><br>   <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span><br>   <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Ear and Labyrinth Disorders </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hypoacusis</span><br>   <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   isolated reports of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span><br>   <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">electrocardiogram QT prolonged</span><br><span class="Italics">   [see <a href="#Section_5.9">Warnings and Precautions (5.9)</a>]</span><br>   <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   isolated reports of allergic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>] </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Hepatobiliary Disorders </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> (including fatal cases)<br>   <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span><br>   <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span><br><span class="Italics">   [see <a href="#Section_5.4">Warnings and Precautions (5.4</a>, <a href="#Section_5.5">5.5)</a>] </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Skin and Subcutaneous Tissue Disorders </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruptions</span> to include:<br>      <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span><br>      <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span><br>      <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span><br><span class="Italics">   [see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>]</span><br><span class="Italics"></span>   <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> reaction <span class="Italics">[see <a href="#Section_5.12">Warnings and Precautions (5.12)</a>]</span><br>   <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span><br>   <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle injury</span>, including rupture<br>   <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Renal and Urinary Disorders </span><br>
</td>
<td class="Rrule" valign="top">   interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>] </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   General Disorders and Administration Site Conditions </span><br>
</td>
<td class="Rrule" valign="top">   multi-organ failure <br>   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Investigations </span><br>
</td>
<td class="Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4260197" conceptname="Prothrombin time increased">prothrombin time prolonged</span><br>   international normalized ratio prolonged<br>   muscle enzymes increased <br>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-8.1"></a><p></p>
<h2>7.1	Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins </h2>
<p class="First"><br><span class="Bold">Levofloxacin Tablets</span><br><br>While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin <span class="Sup"></span>tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine may substantially interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. These agents should be taken at least two hours before or two hours after oral levofloxacin administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-8.2"></a><p></p>
<h2>7.2	Warfarin </h2>
<p class="First"><br>No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for R- and S- warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on levofloxacin absorption and disposition was observed. However, there have been reports during the postmarketing experience in patients that levofloxacin enhances the effects of warfarin. Elevations of the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in the setting of concurrent warfarin and levofloxacin use have been associated with episodes of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if levofloxacin is administered concomitantly with warfarin. Patients should also be monitored for evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><span class="Italics"> [see <a href="#Section_6.3">Adverse Reactions (6.3)</a>; <a href="#Section_17.4">Patient Counseling Information (17.4)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-8.3"></a><p></p>
<h2>7.3	Antidiabetic Agents </h2>
<br><p class="First">Disturbances of blood glucose, including <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, have been reported in patients treated concomitantly with fluoroquinolones and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are coadministered<span class="Italics"> [see <a href="#Section_5.11">Warnings and Precautions (5.11)</a>; <a href="#Section_6.2">Adverse Reactions (6.2)</a>, <a href="#Section_17.4">Patient Counseling Information (17.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.5"></a><a name="section-8.4"></a><p></p>
<h2>7.4	Non-Steroidal Anti-Inflammatory Drugs </h2>
<br><p class="First">The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including levofloxacin, may increase the risk of CNS stimulation and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span><span class="Italics"> [see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.6"></a><a name="section-8.5"></a><p></p>
<h2>7.5	Theophylline </h2>
<br><p class="First">No significant effect of levofloxacin on the plasma concentrations, AUC, and other disposition parameters for theophylline was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of theophylline on levofloxacin absorption and disposition was observed. However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. Therefore, theophylline levels should be closely monitored and appropriate dosage adjustments made when levofloxacin is coadministered. Adverse reactions, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, may occur with or without an elevation in serum theophylline levels<span class="Italics"> [see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.7"></a><a name="section-8.6"></a><p></p>
<h2>7.6	Cyclosporine</h2>
<br><p class="First">No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for cyclosporine was detected in a clinical study involving healthy volunteers. However, elevated serum levels of cyclosporine have been reported in the patient population when coadministered with some other fluoroquinolones. Levofloxacin C<span class="Sub">max</span> and k<span class="Sub">e</span> were slightly lower while T<span class="Sub">max</span> and t½ were slightly longer in the presence of cyclosporine than those observed in other studies without concomitant medication. The differences, however, are not considered to be clinically significant. Therefore, no dosage adjustment is required for levofloxacin or cyclosporine when administered concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.8"></a><a name="section-8.7"></a><p></p>
<h2>7.7	Digoxin </h2>
<br><p class="First">No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Levofloxacin absorption and disposition kinetics were similar in the presence or absence of digoxin. Therefore, no dosage adjustment for levofloxacin or digoxin is required when administered concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.9"></a><a name="section-8.8"></a><p></p>
<h2>7.8	Probenecid and Cimetidine</h2>
<br><p class="First">No significant effect of probenecid or cimetidine on the C<span class="Sub">max</span> of levofloxacin was observed in a clinical study involving healthy volunteers. The AUC and t<span class="Sub">1/2</span> of levofloxacin were higher while CL/F and CL<span class="Sub">R</span> were lower during concomitant treatment of levofloxacin with probenecid or cimetidine compared to levofloxacin alone. However, these changes do not warrant dosage adjustment for levofloxacin when probenecid or cimetidine is coadministered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.10"></a><a name="section-8.9"></a><p></p>
<h2>7.9	Interactions with Laboratory or Diagnostic Testing </h2>
<br><p class="First">Some fluoroquinolones, including levofloxacin, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. Confirmation of positive opiate screens by more specific methods may be necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-9"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><br>Pregnancy Category C. Levofloxacin was not teratogenic in rats at oral doses as high as 810 mg/kg/day which corresponds to 9.4 times the highest recommended human dose based upon relative body surface area, or at intravenous doses as high as 160 mg/kg/day corresponding to 1.9 times the highest recommended human dose based upon relative body surface area. The oral dose of 810 mg/kg/day to rats caused decreased fetal body weight and increased fetal mortality. No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed when rabbits were dosed orally as high as 50 mg/kg/day which corresponds to 1.1 times the highest recommended human dose based upon relative body surface area, or when dosed intravenously as high as 25 mg/kg/day, corresponding to 0.5 times the highest recommended human dose based upon relative body surface area.<br><br>There are, however, no adequate and well-controlled studies in pregnant women. Levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-9.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<br><p class="First">Based on data on other fluoroquinolones and very limited data on levofloxacin, it can be presumed that levofloxacin will be excreted in human milk. Because of the potential for serious adverse reactions from levofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-9.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><br>Quinolones, including levofloxacin, cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> and <span class="product-label-link" type="condition" conceptid="433565" conceptname="Juvenile osteochondrosis of spine">osteochondrosis</span> in juvenile animals of several species <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.10)</a> and <a href="#Section_13.2">Animal Toxicology and/or Pharmacology (13.2)</a>]</span>.<span class="Underline"><br><br>Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure)</span><br><br>Levofloxacin is indicated in pediatric patients 6 months of age and older, for inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure). The risk-benefit assessment indicates that administration of levofloxacin to pediatric patients is appropriate. The safety of levofloxacin in pediatric patients treated for more than 14 days has not been studied <span class="Italics">[see <a href="#Section_1.14">Indications and Usage (1.13)</a>, <a href="#Section_2.3">Dosage and Administration (2.2)</a> and <a href="#Section_14.11">Clinical Studies (14.9)</a>]</span>.<span class="Underline"><br><br><span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span></span><br><br>Levofloxacin is indicated in pediatric patients, 6 months of age and older, for treatment of <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span>, including pneumonic and septicemic <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> due to <span class="Italics">Yersinia pestis </span>(<span class="Italics">Y. pestis</span>) and prophylaxis for <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span>. Efficacy studies of levofloxacin could not be conducted in humans with pneumonic <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals. The risk-benefit assessment indicates that administration of levofloxacin to pediatric patients is appropriate <span class="Italics">[see <a href="#Section_1.14">Indications and Usage (1.14)</a>, <a href="#Section_2.3">Dosage and Administration (2.2)</a> and <a href="#Section_14.10">Clinical Studies (14.10)</a>]. </span><br><br>Safety and effectiveness in pediatric patients below the age of six months have not been established.<br><br><span class="Underline">Adverse Events</span><br><br>In clinical trials, 1534 children (6 months to 16 years of age) were treated with oral and intravenous levofloxacin. Children 6 months to 5 years of age received levofloxacin 10 mg/kg twice a day and children greater than 5 years of age received 10 mg/kg once a day (maximum 500 mg per day) for approximately 10 days.<br><br>A subset of children in the clinical trials (1340 levofloxacin-treated and 893 non-fluoroquinolone-treated) enrolled in a prospective, long-term surveillance study to assess the incidence of protocol-defined <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, tendinopathy, gait abnormality) during 60 days and 1 year following the first dose of the study drug. Children treated with levofloxacin had a significantly higher incidence of <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> when compared to the non-fluoroquinolone-treated children as illustrated in Table 7. <br><br></p>
<a name="ia4f32111-8826-4c4b-8d6e-c5e896c1c33a"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 7: Incidence of <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span> in Pediatric Clinical Trial 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">Follow-up Period </th>
<th class="Lrule Rrule Toprule" align="center">Levofloxacin <br>N = 1340</th>
<th class="Lrule Rrule Toprule" align="center">Non-Fluoroquinolone<span class="Sup">a</span><br>N = 893</th>
<th class="Lrule Rrule Toprule" align="center">p-value<span class="Sup">b</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="4">
<span class="Sup">a </span>Non-Fluoroquinolone: ceftriaxone, amoxicillin/clavulanate, clarithromycin<br><span class="Sup">b </span>2-sided Fisher’s Exact Test<br><span class="Sup">c </span>There were 1199 levofloxacin-treated and 804 non-fluoroquinolone-treated children who had a one-year evaluation visit. However, the incidence of <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> was calculated using all reported events during the specified period for all children enrolled regardless of whether they completed the 1-year evaluation visit.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   60 days </span><br>
</td>
<td class="Rrule" align="center" valign="top">28 (2.1%)<br>
</td>
<td class="Rrule" align="center" valign="top">8 (0.9%)<br>
</td>
<td class="Rrule" align="center" valign="top">p = 0.038<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   1 year<span class="Sup">c</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">46 (3.4%)<br>
</td>
<td class="Rrule" align="center" valign="top">16 (1.8%)<br>
</td>
<td class="Rrule" align="center" valign="top">p = 0.025<br>
</td>
</tr>
</tbody>
</table>
<p><br><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> was the most frequently occurring <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorder</span> in both treatment groups. Most of the <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> in both groups involved multiple weight-bearing joints. Disorders were moderate in 8/46 (17%) children and mild in 35/46 (76%) levofloxacin-treated children and most were treated with analgesics. The median time to resolution was 7 days for levofloxacin-treated children and 9 for non-fluoroquinolone-treated children (approximately 80% resolved within 2 months in both groups). No child had a severe or serious disorder and all <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> resolved without sequelae.<br><br><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> were the most frequently reported adverse events, occurring in similar frequency in the levofloxacin-treated and non-fluoroquinolone-treated children.<br><br>In addition to the events reported in pediatric patients in clinical trials, events reported in adults during clinical trials or postmarketing experience <span class="Italics">[see <a href="#Section_6">Adverse Reactions (6)</a>] </span>may also be expected to occur in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-9.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><br>Geriatric patients are at increased risk for developing severe <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> including <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> when being treated with a fluoroquinolone such as levofloxacin. This risk is further increased in patients receiving concomitant corticosteroid therapy. <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing levofloxacin to elderly patients especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue levofloxacin <span class="Sup"></span>and contact their healthcare provider if any symptoms of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> occur <span class="Italics">[see <a href="#Section_0">Boxed Warning</a>; <a href="#Section_5.1">Warnings and Precautions (5.1)</a>; and <a href="#Section_6.3">Adverse Reactions (6.3)</a>]</span>.<br><br>In phase 3 clinical trials, 1,945 levofloxacin-treated patients (26%) were ≥ 65 years of age. Of these, 1,081 patients (14%) were between the ages of 65 and 74 and 864 patients (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.<br><br>Severe, and sometimes fatal, cases of hepatotoxicity have been reported postmarketing in association with levofloxacin. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. Levofloxacin should be discontinued immediately if the patient develops signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> <span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>].</span><br><br>Elderly patients may be more susceptible to drug-associated effects on the QT interval. Therefore, precaution should be taken when using levofloxacin with concomitant drugs that can result in prolongation of the QT interval (e.g., Class IA or Class III antiarrhythmics) or in patients with risk factors for <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> (e.g., known QT prolongation, uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>)<span class="Italics"> [see <a href="#Section_5.9">Warnings and Precautions (5.9)</a>].</span><br><br>The pharmacokinetic properties of levofloxacin in younger adults and elderly adults do not differ significantly when creatinine clearance is taken into consideration. However, since the drug is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-9.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<br><p class="First">Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance &lt;50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of levofloxacin are not required following hemodialysis or CAPD <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.3)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-9.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<br><p class="First">Pharmacokinetic studies in hepatically impaired patients have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><br>In the event of an acute overdosage, the stomach should be emptied. The patient should be observed and appropriate hydration maintained. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis.<br><br>Levofloxacin exhibits a low potential for acute toxicity. Mice, rats, dogs and monkeys exhibited the following clinical signs after receiving a single high dose of levofloxacin: <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, decreased locomotor activity, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">prostration</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Doses in excess of 1500 mg/kg orally and 250 mg/kg IV produced significant mortality in rodents.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"><br>Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral administration. Chemically, levofloxacin, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. The chemical name is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate.<br><br><span class="Bold">Figure 1: The Chemical Structure of Levofloxacin</span><br><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=814450ae-439e-4a5d-8c60-9b21b6f14be5&amp;name=levofloxacin-str.jpg"><br>The molecular formula is C<span class="Sub">18</span>H<span class="Sub">20</span>FN<span class="Sub">3</span>O<span class="Sub">4</span> • ½ H<span class="Sub">2</span>O and the molecular weight is 370.38. Levofloxacin USP is a <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> or bright  yellow, crystalline powder. The molecule exists as a zwitterion at the pH conditions in the small intestine.<br><br>The data demonstrate that from pH 0.6 to 5.8, the solubility of levofloxacin USP is essentially constant (approximately 100 mg/mL). Levofloxacin USP is considered <span class="Italics">soluble to freely soluble</span> in this pH range, as defined by USP nomenclature. Above pH 5.8, the solubility increases rapidly to its maximum at pH 6.7 (272 mg/mL) and is considered <span class="Italics">freely soluble </span>in this range. Above pH 6.7, the solubility decreases and reaches a minimum value (about 50 mg/mL) at a pH of approximately 6.9.<br><br>Levofloxacin USP has the potential to form stable coordination compounds with many metal ions. This <span class="Italics">in vitro</span> chelation potential has the following formation order:  Al<span class="Sup">+3</span>&gt;Cu<span class="Sup">+2</span>&gt;Zn<span class="Sup">+2</span>&gt;Mg<span class="Sup">+2</span>&gt;Ca<span class="Sup">+2</span>. <br><span class="Bold"><br>Excipients and Description of Dosage Forms</span><br><br>Levofloxacin tablets are available as film-coated tablets and contain the following inactive ingredients:<br><br>250 mg, 500 mg and 750 mg (as expressed in the anhydrous form): croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, polysorbate 80, and titanium dioxide. In addition 250 mg contains iron oxide red and 500 mg contains iron oxide red and iron oxide yellow.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<br><p class="First">Levofloxacin is a member of the fluoroquinolone class of antibacterial agents <span class="Italics">[see <a href="#Section_12.4">Clinical Pharmacology (12.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><br>The mean ± SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following oral tablet, oral solution, or intravenous (IV) doses of levofloxacin are summarized in Table 8.<br></p>
<a name="iaa627765-b615-44ce-8e9d-31d84497adf2"></a><table border="0" cellpadding="0" cellspacing="0" width="895">
<caption><span>Table 8: Mean ± SD Levofloxacin PK Parameters  
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Regimen</th>
<th class="Lrule Rrule Toprule" align="center">C<span class="Sub">max</span><br>(mcg/mL)</th>
<th class="Lrule Rrule Toprule" align="center">T<span class="Sub">max</span><br>(h)</th>
<th class="Lrule Rrule Toprule" align="center">AUC<br>(mcg•h/mL) </th>
<th class="Lrule Rrule Toprule" align="center">CL/F<span class="Sup">1</span><br>(mL/min) </th>
<th class="Lrule Rrule Toprule" align="center">Vd/F<span class="Sup">2</span><br>(L)</th>
<th class="Lrule Rrule Toprule" align="center">t<span class="Sub">1/2</span><br>(h)</th>
<th class="Lrule Rrule Toprule" align="center">CL<span class="Sub">R</span><br>(mL/min) </th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="8">
<span class="Sup">1 </span>clearance/bioavailability<br><span class="Sup">2</span> volume of distribution/bioavailability<br><span class="Sup">3 </span>healthy males 18 to 53 years of age<br><span class="Sup">4</span> 60 min infusion for 250 mg and 500 mg doses, 90 min infusion for 750 mg dose<br><span class="Sup">5 </span>healthy male and female subjects 18 to 54 years of age<br><span class="Sup">6 </span>500 mg every 48 h for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLCR 20 to 50 mL/min) and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the respiratory tract or skin<br><span class="Sup">7 </span>dose-normalized values (to 500 mg dose), estimated by population pharmacokinetic modeling<br><span class="Sup">8 </span>healthy males 22 to 75 years of age<br><span class="Sup">9 </span>healthy females 18 to 80 years of age<br><span class="Sup">10 </span>young healthy male and female subjects 18 to 36 years of age<br><span class="Sup">11 </span>healthy elderly male and female subjects 66 to 80 years of age<br><span class="Sup">12 </span>healthy males and females 19 to 55 years of age. <br><span class="Sup">*</span> Absolute bioavailability; F=0.99 ± 0.08 from a 500 mg tablet and F=0.99 ± 0.06 from a 750 mg tablet; <br>ND=not determined.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" colspan="3" valign="top">
<span class="Bold">   Single dose </span><br>
</td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   250 mg oral tablet<span class="Sup">3</span><br>
</td>
<td class="Rrule" align="center" valign="top">2.8 ± 0.4<br>
</td>
<td class="Rrule" align="center" valign="top">1.6 ± 1<br>
</td>
<td class="Rrule" align="center" valign="top">27.2 ± 3.9<br>
</td>
<td class="Rrule" align="center" valign="top">156 ± 20<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">7.3 ± 0.9 <br>
</td>
<td class="Rrule" align="center" valign="top">142 ± 21<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   500 mg oral tablet<span class="Sup">3*</span><br>
</td>
<td class="Rrule" align="center" valign="top">5.1 ± 0.8<br>
</td>
<td class="Rrule" align="center" valign="top">1.3 ± 0.6<br>
</td>
<td class="Rrule" align="center" valign="top">47.9 ± 6.8<br>
</td>
<td class="Rrule" align="center" valign="top">178 ± 28 <br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">6.3 ± 0.6<br>
</td>
<td class="Rrule" align="center" valign="top">103 ± 30<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   500 mg oral solution<span class="Sup">12</span><br>
</td>
<td class="Rrule" align="center" valign="top">5.8 ± 1.8<br>
</td>
<td class="Rrule" align="center" valign="top">0.8 ± 0.7 <br>
</td>
<td class="Rrule" align="center" valign="top">47.8 ± 10.8<br>
</td>
<td class="Rrule" align="center" valign="top">183 ± 40<br>
</td>
<td class="Rrule" align="center" valign="top">112 ± 37.2 <br>
</td>
<td class="Rrule" align="center" valign="top">7 ± 1.4<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   500 mg IV<span class="Sup">3</span><br>
</td>
<td class="Rrule" align="center" valign="top">6.2 ± 1<br>
</td>
<td class="Rrule" align="center" valign="top">1 ± 0.1<br>
</td>
<td class="Rrule" align="center" valign="top">48.3 ± 5.4<br>
</td>
<td class="Rrule" align="center" valign="top">175 ± 20<br>
</td>
<td class="Rrule" align="center" valign="top">90 ± 11<br>
</td>
<td class="Rrule" align="center" valign="top">6.4 ± 0.7 <br>
</td>
<td class="Rrule" align="center" valign="top">112 ± 25<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   750 mg oral tablet<span class="Sup">5*</span><br>
</td>
<td class="Rrule" align="center" valign="top">9.3 ± 1.6<br>
</td>
<td class="Rrule" align="center" valign="top">1.6 ± 0.8<br>
</td>
<td class="Rrule" align="center" valign="top">101 ± 20<br>
</td>
<td class="Rrule" align="center" valign="top">129 ± 24<br>
</td>
<td class="Rrule" align="center" valign="top">83 ± 17<br>
</td>
<td class="Rrule" align="center" valign="top">7.5 ± 0.9<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   750 mg IV<span class="Sup">5</span><br>
</td>
<td class="Rrule" align="center" valign="top">11.5 ± 4<span class="Sup">4 </span><br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">110 ± 40<br>
</td>
<td class="Rrule" align="center" valign="top">126 ± 39<br>
</td>
<td class="Rrule" align="center" valign="top">75 ± 13<br>
</td>
<td class="Rrule" align="center" valign="top">7.5 ± 1.6<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="3" valign="top">
<span class="Bold">   Multiple dose </span><br>
</td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   500 mg every 24 h oral tablet<span class="Sup">3</span><br>
</td>
<td class="Rrule" align="center" valign="top">5.7 ± 1.4<br>
</td>
<td class="Rrule" align="center" valign="top">1.1 ± 0.4<br>
</td>
<td class="Rrule" align="center" valign="top">47.5 ± 6.7<br>
</td>
<td class="Rrule" align="center" valign="top">175 ± 25<br>
</td>
<td class="Rrule" align="center" valign="top">102 ± 22<br>
</td>
<td class="Rrule" align="center" valign="top">7.6 ± 1.6<br>
</td>
<td class="Rrule" align="center" valign="top">116 ± 31<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   500 mg every 24 h IV<span class="Sup">3</span><br>
</td>
<td class="Rrule" align="center" valign="top">6.4 ± 0.8<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">54.6 ± 11.1<br>
</td>
<td class="Rrule" align="center" valign="top">158 ± 29<br>
</td>
<td class="Rrule" align="center" valign="top">91 ± 12<br>
</td>
<td class="Rrule" align="center" valign="top">7 ± 0.8<br>
</td>
<td class="Rrule" align="center" valign="top">99 ± 28<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   500 mg or 250 mg every 24 h IV, patients with <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span><span class="Sup">6 </span><br>
</td>
<td class="Rrule" align="center" valign="top">8.7 ± 4<span class="Sup">7</span><br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">72.5 ± 51.2<span class="Sup">7</span><br>
</td>
<td class="Rrule" align="center" valign="top">154 ± 72<br>
</td>
<td class="Rrule" align="center" valign="top">111 ± 58<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   750 mg every 24 h oral tablet<span class="Sup">5</span><br>
</td>
<td class="Rrule" align="center" valign="top">8.6 ± 1.9<br>
</td>
<td class="Rrule" align="center" valign="top">1.4 ± 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">90.7 ± 17.6<br>
</td>
<td class="Rrule" align="center" valign="top">143 ± 29<br>
</td>
<td class="Rrule" align="center" valign="top">100 ± 16<br>
</td>
<td class="Rrule" align="center" valign="top">8.8 ± 1.5<br>
</td>
<td class="Rrule" align="center" valign="top">116 ± 28<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   750 mg every 24 h IV<span class="Sup">5</span><br>
</td>
<td class="Rrule" align="center" valign="top">12.1 ± 4.1<span class="Sup">4 </span><br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">108 ± 34<br>
</td>
<td class="Rrule" align="center" valign="top">126 ± 37<br>
</td>
<td class="Rrule" align="center" valign="top">80 ± 27<br>
</td>
<td class="Rrule" align="center" valign="top">7.9 ± 1.9<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="3" valign="top">
<span class="Bold">   500 mg oral tablet single dose, effects of gender and age: </span><br>
</td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Male<span class="Sup">8</span><br>
</td>
<td class="Rrule" align="center" valign="top">5.5 ± 1.1<br>
</td>
<td class="Rrule" align="center" valign="top">1.2 ± 0.4<br>
</td>
<td class="Rrule" align="center" valign="top">54.4 ± 18.9<br>
</td>
<td class="Rrule" align="center" valign="top">166 ± 44<br>
</td>
<td class="Rrule" align="center" valign="top">89 ± 13<br>
</td>
<td class="Rrule" align="center" valign="top">7.5 ± 2.1<br>
</td>
<td class="Rrule" align="center" valign="top">126 ± 38<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Female<span class="Sup">9</span><br>
</td>
<td class="Rrule" align="center" valign="top">7 ± 1.6<br>
</td>
<td class="Rrule" align="center" valign="top">1.7 ± 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">67.7 ± 24.2<br>
</td>
<td class="Rrule" align="center" valign="top">136 ± 44<br>
</td>
<td class="Rrule" align="center" valign="top">62 ± 16<br>
</td>
<td class="Rrule" align="center" valign="top">6.1 ± 0.8<br>
</td>
<td class="Rrule" align="center" valign="top">106 ± 40<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Young<span class="Sup">10</span><br>
</td>
<td class="Rrule" align="center" valign="top">5.5 ± 1<br>
</td>
<td class="Rrule" align="center" valign="top">1.5 ± 0.6<br>
</td>
<td class="Rrule" align="center" valign="top">47.5 ± 9.8<br>
</td>
<td class="Rrule" align="center" valign="top">182 ± 35<br>
</td>
<td class="Rrule" align="center" valign="top">83 ± 18<br>
</td>
<td class="Rrule" align="center" valign="top">6 ± 0.9<br>
</td>
<td class="Rrule" align="center" valign="top">140 ± 33<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Elderly<span class="Sup">11</span><br>
</td>
<td class="Rrule" align="center" valign="top">7 ± 1.6<br>
</td>
<td class="Rrule" align="center" valign="top">1.4 ± 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">74.7 ± 23.3<br>
</td>
<td class="Rrule" align="center" valign="top">121 ± 33<br>
</td>
<td class="Rrule" align="center" valign="top">67 ± 19<br>
</td>
<td class="Rrule" align="center" valign="top">7.6 ± 2<br>
</td>
<td class="Rrule" align="center" valign="top">91 ± 29<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="3" valign="top">
<span class="Bold">   500 mg oral single dose tablet, patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>: </span><br>
</td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
<td class="Rrule" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   CLCR 50 to 80 mL/min <br>
</td>
<td class="Rrule" align="center" valign="top">7.5 ± 1.8<br>
</td>
<td class="Rrule" align="center" valign="top">1.5 ± 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">95.6 ± 11.8<br>
</td>
<td class="Rrule" align="center" valign="top">88 ± 10<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">9.1 ± 0.9<br>
</td>
<td class="Rrule" align="center" valign="top">57 ± 8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   CLCR 20 to 49 mL/min <br>
</td>
<td class="Rrule" align="center" valign="top">7.1 ± 3.1<br>
</td>
<td class="Rrule" align="center" valign="top">2.1 ± 1.3<br>
</td>
<td class="Rrule" align="center" valign="top">182.1 ± 62.6<br>
</td>
<td class="Rrule" align="center" valign="top">51 ± 19<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">27 ± 10<br>
</td>
<td class="Rrule" align="center" valign="top">26 ± 13<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   CLCR &lt;20 mL/min <br>
</td>
<td class="Rrule" align="center" valign="top">8.2 ± 2.6<br>
</td>
<td class="Rrule" align="center" valign="top">1.1 ± 1<br>
</td>
<td class="Rrule" align="center" valign="top">263.5 ± 72.5<br>
</td>
<td class="Rrule" align="center" valign="top">33 ± 8<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">35 ± 5<br>
</td>
<td class="Rrule" align="center" valign="top">13 ± 3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Hemodialysis <br>
</td>
<td class="Rrule" align="center" valign="top">5.7 ± 1<br>
</td>
<td class="Rrule" align="center" valign="top">2.8 ± 2.2<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">76 ± 42<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">   CAPD <br>
</td>
<td class="Rrule" align="center" valign="top">6.9 ± 2.3<br>
</td>
<td class="Rrule" align="center" valign="top">1.4 ± 1.1<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">51 ± 24<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
</tr>
</tbody>
</table>
<p><br><span class="Bold">Absorption</span><br><br>Levofloxacin is rapidly and essentially completely absorbed after oral administration. Peak plasma concentrations are usually attained one to two hours after oral dosing. The absolute bioavailability of levofloxacin from a 500 mg tablet and a 750 mg tablet of levofloxacin <span class="Sup"></span>are both approximately 99%, demonstrating complete oral absorption of levofloxacin. Following a single intravenous dose of levofloxacin to healthy volunteers, the mean ± SD peak plasma concentration attained was 6.2 ± 1 mcg/mL after a 500 mg dose infused over 60 minutes and 11.5 ± 4 mcg/mL after a 750 mg dose infused over 90 minutes. Levofloxacin oral solution and tablet formulations are bioequivalent.<br><br>Levofloxacin pharmacokinetics are linear and predictable after single and multiple oral or IV dosing regimens. Steady-state conditions are reached within 48 hours following a 500 mg or 750 mg once-daily dosage regimen. The mean ± SD peak and trough plasma concentrations attained following multiple once-daily oral dosage regimens were approximately 5.7 ± 1.4 and 0.5 ± 0.2 mcg/mL after the 500 mg doses, and 8.6 ± 1.9 and 1.1 ± 0.4 mcg/mL after the 750 mg doses, respectively. The mean ± SD peak and trough plasma concentrations attained following multiple once-daily IV regimens were approximately 6.4 ± 0.8 and 0.6 ± 0.2 mcg/mL after the 500 mg doses, and 12.1 ± 4.1 and 1.3 ± 0.71 mcg/mL after the 750 mg doses, respectively. Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration. Therefore, levofloxacin tablets can be administered without regard to food. It is recommended that levofloxacin oral solution be taken 1 hour before or 2 hours after eating.<br><br>The plasma concentration profile of levofloxacin after IV administration is similar and comparable in extent of exposure (AUC) to that observed for levofloxacin tablets when equal doses (mg/mg) are administered. Therefore, the oral and IV routes of administration can be considered interchangeable <span class="Italics">(see Figure 2 and Figure 3).</span><br><img alt="Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=814450ae-439e-4a5d-8c60-9b21b6f14be5&amp;name=levofloxacin-fig1.jpg"><img alt="Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=814450ae-439e-4a5d-8c60-9b21b6f14be5&amp;name=levofloxacin-fig2.jpg"><span class="Bold">Distribution</span><br><br>The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues. Levofloxacin reaches its peak levels in skin tissues and in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid of healthy subjects at approximately 3 hours after dosing. The skin tissue biopsy to plasma AUC ratio is approximately 2 and the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid to plasma AUC ratio is approximately 1 following multiple once-daily oral administration of 750 mg and 500 mg doses of levofloxacin, respectively, to healthy subjects. Levofloxacin also penetrates well into lung tissues. Lung tissue concentrations were generally 2- to 5-fold higher than plasma concentrations and ranged from approximately 2.4 to 11.3 mcg/g over a 24-hour period after a single 500 mg oral dose.<span class="Italics"><br><br>In vitro</span>, over a clinically relevant range (1 to 10 mcg/mL) of serum/plasma levofloxacin concentrations, levofloxacin is approximately 24 to 38% bound to serum proteins across all species studied, as determined by the equilibrium dialysis method. Levofloxacin is mainly bound to serum albumin in humans. Levofloxacin binding to serum proteins is independent of the drug concentration.<span class="Bold"><br><br>Metabolism</span><br><br>Levofloxacin is stereochemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine. Following oral administration, approximately 87% of an administered dose was recovered as unchanged drug in urine within 48 hours, whereas less than 4% of the dose was recovered in feces in 72 hours. Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites, the only metabolites identified in humans. These metabolites have little relevant pharmacological activity.<span class="Bold"><br><br>Excretion</span><br><br>Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously. The mean apparent total body clearance and renal clearance range from approximately 144 to 226 mL/min and 96 to 142 mL/min, respectively. Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion of levofloxacin occurs in addition to its glomerular filtration. Concomitant administration of either cimetidine or probenecid results in approximately 24% and 35% reduction in the levofloxacin renal clearance, respectively, indicating that secretion of levofloxacin occurs in the renal proximal tubule. No levofloxacin crystals were found in any of the urine samples freshly collected from subjects receiving levofloxacin.<span class="Bold"><br><br>Geriatric</span><br><br>There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects when the subjects’ differences in creatinine clearance are taken into consideration. Following a 500 mg oral dose of levofloxacin to healthy elderly subjects (66 to 80 years of age), the mean terminal plasma elimination half-life of levofloxacin was about 7.6 hours, as compared to approximately 6 hours in younger adults. The difference was attributable to the variation in renal function status of the subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by age. Levofloxacin <span class="Sup"></span>dose adjustment based on age alone is not necessary <span class="Italics">[see <a href="#Section_8.5">Use in Specific Populations (8.5)</a>]</span>.<span class="Bold"><br><br>Pediatrics</span><br><br>The pharmacokinetics of levofloxacin following a single 7 mg/kg intravenous dose were investigated in pediatric patients ranging in age from 6 months to 16 years. Pediatric patients cleared levofloxacin faster than adult patients, resulting in lower plasma exposures than adults for a given mg/kg dose. Subsequent pharmacokinetic analyses predicted that a dosage regimen of 8 mg/kg every 12 hours (not to exceed 250 mg per dose) for pediatric patients 6 months to 17 years of age would achieve comparable steady state plasma exposures (AUC<span class="Sub">0-24</span> and C<span class="Sub">max</span>) to those observed in adult patients administered 500 mg of levofloxacin once every 24 hours.<span class="Bold"><br><br>Gender</span><br><span class="Bold"></span><br>There are no significant differences in levofloxacin pharmacokinetics between male and female subjects when subjects’ differences in creatinine clearance are taken into consideration. Following a 500 mg oral dose of levofloxacin to healthy male subjects, the mean terminal plasma elimination half-life of levofloxacin was about 7.5 hours, as compared to approximately 6.1 hours in female subjects. This difference was attributable to the variation in renal function status of the male and female subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by the gender of the subjects. Dose adjustment based on gender alone is not necessary.<span class="Bold"><br><br>Race</span><br><br>The effect of race on levofloxacin pharmacokinetics was examined through a covariate analysis performed on data from 72 subjects: 48 white and 24 non-white. The apparent total body clearance and apparent volume of distribution were not affected by the race of the subjects.<span class="Bold"><br><br><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><br><br>Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance &lt; 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of levofloxacin are not required following hemodialysis or CAPD <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.3)</a>, <a href="#Section_8.6">Use in Specific Populations (8.6)</a>].</span><span class="Bold"><br><br><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><br><br>Pharmacokinetic studies in hepatically impaired patients have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#Section_8.7">Use in Specific Populations (8.7)</a>]</span>.<span class="Bold"><br><br><span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infection</span></span><br><br>The pharmacokinetics of levofloxacin in patients with serious community-acquired <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> are comparable to those observed in healthy subjects.<br><span class="Bold"><br>Drug-Drug Interactions</span><br><br>The potential for pharmacokinetic drug interactions between levofloxacin and antacids, warfarin, theophylline, cyclosporine, digoxin, probenecid, and cimetidine has been evaluated <span class="Italics">[see <a href="#Section_7">Drug Interactions (7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4"></a><a name="section-12.3"></a><p></p>
<h2>12.4	Microbiology </h2>
<p class="First"><br><span class="Bold">Mechanism of Action</span><br><br>Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the L-isomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair and recombination.<span class="Bold"><br><br>Mechanism of Resistance</span><br><br>Fluoroquinolone resistance can arise through mutations in defined regions of DNA gyrase or topoisomerase IV, termed the Quinolone-Resistance Determining Regions (QRDRs), or through altered efflux. <br><br>Fluoroquinolones, including levofloxacin, differ in chemical structure and mode of action from aminoglycosides, macrolides and ⛚-lactam antibiotics, including penicillins. Fluoroquinolones may, therefore, be active against bacteria resistant to these antimicrobials.<br><br>Resistance to levofloxacin due to spontaneous mutation<span class="Italics"> in vitro</span> is a rare occurrence (range: 10<span class="Sup">-9</span> to 10<span class="Sup">-10</span>). Cross-resistance has been observed between levofloxacin and some other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to levofloxacin.<span class="Bold"><br><br>Activity <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span><br></span><br>Levofloxacin has<span class="Italics"> in vitro</span> activity against Gram-negative and Gram-positive bacteria.<br><br>Levofloxacin has been shown to be active against most isolates of the following bacteria both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in <span class="Italics"><a href="#Section_1">Indications and Usage (1)</a>:</span><span class="Bold"><br><br>Gram-Positive Bacteria</span><span class="Italics"><br><br>Enterococcus faecalis <br></span><span class="Italics">Staphylococcus aureus</span> (methicillin-susceptible isolates)<br><span class="Italics">Staphylococcus epidermidis </span>(methicillin-susceptible isolates)<br><span class="Italics">Staphylococcus saprophyticus</span><br><span class="Italics">Streptococcus pneumoniae</span> (including multi-drug resistant isolates [MDRSP])* <br><span class="Italics">Streptococcus pyogenes</span><br><br>*MDRSP (Multi-drug resistant <span class="Italics">Streptococcus pneumoniae</span>) isolates are isolates resistant to two or more of the following antibiotics: penicillin (MIC ≥2 mcg/mL), 2<span class="Sup">nd</span> generation cephalosporins, e.g., cefuroxime; macrolides, tetracyclines and trimethoprim/sulfamethoxazole.<span class="Bold"><br><br>Gram-Negative Bacteria</span><span class="Italics"><br><br>Enterobacter cloacae</span><br><span class="Italics">Escherichia coli</span><br><span class="Italics">Haemophilus influenzae</span><br><span class="Italics">Haemophilus parainfluenzae</span><br><span class="Italics">Klebsiella pneumoniae</span><br><span class="Italics">Legionella pneumophila</span><br><span class="Italics">Moraxella catarrhalis</span><br><span class="Italics">Proteus mirabilis</span><br><span class="Italics">Pseudomonas aeruginosa </span><br><span class="Italics">Serratia marcescens</span><br><span class="Bold"><br>Other Bacteria</span><span class="Italics"><br><br>Chlamydophila pneumoniae</span><br><span class="Italics">Mycoplasma pneumoniae</span><br><br>The following <span class="Italics">in vitro</span> data are available, <span class="Underline">but their clinical significance is unknown:</span> Levofloxacin exhibits<span class="Italics"> in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC values) of 2 mcg/mL or less against most (≥90%) isolates of the following microorganisms; however, the safety and effectiveness of levofloxacin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria have not been established in adequate and well-controlled clinical trials.<span class="Bold"><br><br>Gram-Positive Bacteria</span><span class="Italics"><br><br>Staphylococcus haemolyticus</span><br>⛚-hemolytic <span class="Italics">Streptococcus (Group C/F)</span><br>⛚<span class="Italics">-hemolytic Streptococcus (Group G)</span><br><span class="Italics">Streptococcus agalactiae</span><br><span class="Italics">Streptococcus milleri</span><br>Viridans group <span class="Italics">streptococci</span><br><span class="Italics">Bacillus anthracis</span><span class="Bold"><br><br>Gram-Negative Bacteria</span><span class="Italics"><br><br>Acinetobacter baumannii</span><br><span class="Italics">Acinetobacter lwoffii</span><br><span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span><br><span class="Italics">Citrobacter koseri</span><br><span class="Italics">Citrobacter freundii</span><br><span class="Italics">Enterobacter aerogenes</span><br><span class="Italics">Enterobacter sakazakii</span><br><span class="Italics">Klebsiella oxytoca</span><br><span class="Italics">Morganella morganii</span><br><span class="Italics">Pantoea agglomerans</span><br><span class="Italics">Proteus vulgaris</span><br><span class="Italics">Providencia rettgeri</span><br><span class="Italics">Providencia stuartii</span><br><span class="Italics">Pseudomonas fluorescens</span><br><span class="Italics">Yersinia pestis</span><span class="Bold"><br><br>Anaerobic Gram-Positive Bacteria</span><span class="Italics"><br><br>Clostridium perfringens</span><br><span class="Bold"><br>Susceptibility Tests</span><br><br>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drug products used in the resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.<br><br><span class="Bold">Dilution techniques </span></p>
<p><br>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs values provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC values should be determined using a standardized procedure. Standardized procedures are based on a dilution method</p>
<span class="Sup">1,2,4</span><p> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of levofloxacin powder. The MIC values should be interpreted according to the criteria outlined in Table 9. <br></p>
<span class="Bold">Diffusion techniques: </span><p><br>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2,3</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5 mcg levofloxacin to test the susceptibility of bacteria to levofloxacin.<br><br>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg levofloxacin disk should be interpreted according to the criteria outlined in Table 9.  <br></p>
<a name="id29c8e31-fb72-41be-8444-217161fd2f29"></a><table border="0" cellpadding="0" cellspacing="0" width="606">
<caption><span>Table 9: Susceptibility Test Interpretive Criteria for Levofloxacin 
			</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" rowspan="2">Pathogen </th>
<th class="Lrule Rrule Toprule" align="center" colspan="3">Minimum Inhibitory<br>Concentrations (mcg/mL)</th>
<th class="Lrule Rrule Toprule" align="center" colspan="3">Disk Diffusion<br>(zone diameter in mm)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">S</th>
<th class="Lrule Rrule Toprule" align="center">I</th>
<th class="Lrule Rrule Toprule" align="center">R</th>
<th class="Lrule Rrule Toprule" align="center">S</th>
<th class="Lrule Rrule Toprule" align="center">I</th>
<th class="Lrule Rrule Toprule" align="center">R</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="7">S = Susceptible, I = Intermediate, R = Resistant <br><span class="Sup">a </span>The current absence of data on resistant isolates precludes defining any categories other than “Susceptible.? Isolates yielding MIC/zone diameter results suggestive of a “nonsusceptible? category should be submitted to a reference laboratory for further testing. <br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Enterobacteriaceae </span><br>
</td>
<td class="Rrule" align="center" valign="top">≤2<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">≥8<br>
</td>
<td class="Rrule" align="center" valign="top">≥17<br>
</td>
<td class="Rrule" align="center" valign="top">14-16<br>
</td>
<td class="Rrule" align="center" valign="top">≤13<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Enterococcus faecalis </span><br>
</td>
<td class="Rrule" align="center" valign="top">≤2<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">≥8<br>
</td>
<td class="Rrule" align="center" valign="top">≥17<br>
</td>
<td class="Rrule" align="center" valign="top">14-16<br>
</td>
<td class="Rrule" align="center" valign="top">≤13<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Staphylococcus</span> species <br>
</td>
<td class="Rrule" align="center" valign="top">≤2<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">≥8<br>
</td>
<td class="Rrule" align="center" valign="top">≥17<br>
</td>
<td class="Rrule" align="center" valign="top">14-16<br>
</td>
<td class="Rrule" align="center" valign="top">≤13<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Pseudomonas aeruginosa </span><br>
</td>
<td class="Rrule" align="center" valign="top">≤2<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">≥8<br>
</td>
<td class="Rrule" align="center" valign="top">≥17<br>
</td>
<td class="Rrule" align="center" valign="top">14-16<br>
</td>
<td class="Rrule" align="center" valign="top">≤13<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Haemophilus influenzae </span><br>
</td>
<td class="Rrule" align="center" valign="top">≤2<br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">≥17<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Haemophilus parainfluenzae </span><br>
</td>
<td class="Rrule" align="center" valign="top">≤2<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">≥17<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Streptococcus pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">≤2<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">≥8<br>
</td>
<td class="Rrule" align="center" valign="top">≥17<br>
</td>
<td class="Rrule" align="center" valign="top">14-16<br>
</td>
<td class="Rrule" align="center" valign="top">≤13<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Streptococcus pyogenes </span><br>
</td>
<td class="Rrule" align="center" valign="top">≤2<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">≥8<br>
</td>
<td class="Rrule" align="center" valign="top">≥17<br>
</td>
<td class="Rrule" align="center" valign="top">14-16<br>
</td>
<td class="Rrule" align="center" valign="top">≤13<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Yersinia pestis<span class="Sup">4</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">≤0.25 <br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Bacillus anthracis<span class="Sup">4</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">≤0.25 <br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
</tbody>
</table>
<p><br>A report of <span class="Italics">Susceptible</span> indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of <span class="Italics">Intermediate</span> indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of <span class="Italics">Resistant</span> indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.<br></p>
<span class="Bold"><br>Quality Control: </span><p><br><br>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.<span class="Sup">1,2,3,4 </span>Standard levofloxacin powder should provide the range of MIC values noted in Table 10. For the diffusion technique using the 5 mcg disk, the criteria in Table 10 should be achieved. <br></p>
<a name="i2451d410-9d4e-4c88-8361-4089efd61ee3"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 10: Quality Control Ranges for Susceptibility Testing 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Microorganism</th>
<th class="Lrule Rrule Toprule" align="center">Microorganism<br>QC Number</th>
<th class="Lrule Rrule Toprule" align="center">MIC (mcg/mL)</th>
<th class="Lrule Rrule Toprule" align="center">Disk Diffusion<br>(zone diameter in mm)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Enterococcus faecalis </span><br>
</td>
<td class="Rrule" align="center" valign="top">ATCC 29212<br>
</td>
<td class="Rrule" align="center" valign="top">0.25 – 2<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Escherichia coli </span><br>
</td>
<td class="Rrule" align="center" valign="top">ATCC 25922<br>
</td>
<td class="Rrule" align="center" valign="top">0.008 – 0.06<br>
</td>
<td class="Rrule" align="center" valign="top">29 – 37<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Escherichia coli</span><br>
</td>
<td class="Rrule" align="center" valign="top">ATCC 35218<br>
</td>
<td class="Rrule" align="center" valign="top">0.015 – 0.06<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Haemophilus influenzae </span><br>
</td>
<td class="Rrule" align="center" valign="top">ATCC 49247<br>
</td>
<td class="Rrule" align="center" valign="top">0.008 – 0.03<br>
</td>
<td class="Rrule" align="center" valign="top">32 – 40<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Pseudomonas aeruginosa </span><br>
</td>
<td class="Rrule" align="center" valign="top">ATCC 27853<br>
</td>
<td class="Rrule" align="center" valign="top">0.5 – 4<br>
</td>
<td class="Rrule" align="center" valign="top">19 – 26<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Staphylococcus aureus </span><br>
</td>
<td class="Rrule" align="center" valign="top">ATCC 29213<br>
</td>
<td class="Rrule" align="center" valign="top">0.06 – 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Staphylococcus aureus </span><br>
</td>
<td class="Rrule" align="center" valign="top">ATCC 25923<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">25 – 30<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics"> Streptococcus pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">ATCC 49619<br>
</td>
<td class="Rrule" align="center" valign="top">0.5 – 2<br>
</td>
<td class="Rrule" align="center" valign="top">20 – 25<br>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><br>In a lifetime bioassay in rats, levofloxacin exhibited no carcinogenic potential following daily dietary administration for 2 years; the highest dose (100 mg/kg/day) <span class="Italics"></span>was 1.4 times the highest recommended human dose (750 mg) based upon relative body surface area. Levofloxacin did not shorten the time to tumor development of UV-induced <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> in hairless albino (Skh-1) mice at any levofloxacin dose level and was therefore not photo-carcinogenic under conditions of this study. Dermal levofloxacin concentrations in the hairless mice ranged from 25 to 42 mcg/g at the highest levofloxacin dose level (300 mg/kg/day) used in the photo-carcinogenicity study. By comparison, dermal levofloxacin concentrations in human subjects receiving 750 mg of levofloxacin averaged approximately 11.8 mcg/g at C<span class="Sub">max</span>.<br><br>Levofloxacin was not mutagenic in the following assays: Ames bacterial mutation assay (<span class="Italics">S. typhimurium</span> and <span class="Italics">E. coli)</span>, CHO/HGPRT forward mutation assay, mouse micronucleus test, mouse dominant lethal test, rat unscheduled DNA synthesis assay, and the mouse sister chromatid exchange assay. It was positive in the <span class="Italics">in vitro</span> chromosomal aberration (CHL cell line) and sister chromatid exchange (CHL/IU cell line) assays.<br><br>Levofloxacin caused no impairment of fertility or reproductive performance in rats at oral doses as high as 360 mg/kg/day, corresponding to 4.2 times the highest recommended human dose based upon relative body surface area and intravenous doses as high as 100 mg/kg/day, corresponding to 1.2 times the highest recommended human dose based upon relative body surface area.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="Section_13.2"></a><a name="section-13.2"></a><p></p>
<h2>13.2	Animal Toxicology and/or Pharmacology</h2>
<p class="First"><br>Levofloxacin and other quinolones have been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of most species tested <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.10)</a>].</span> In immature dogs (4 to 5 months old), oral doses of 10 mg/kg/day for 7 days and intravenous doses of 4 mg/kg/day for 14 days of levofloxacin resulted in arthropathic lesions. Administration at oral doses of 300 mg/kg/day for 7 days and intravenous doses of 60 mg/kg/day for 4 weeks produced <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in juvenile rats. Three-month old beagle dogs dosed orally with levofloxacin at 40 mg/kg/day exhibited clinically severe arthrotoxicity resulting in the termination of dosing at Day 8 of a 14-day dosing routine. Slight musculoskeletal clinical effects, in the absence of gross pathological or histopathological effects, resulted from the lowest dose level of 2.5 mg/kg/day (approximately 0.2-fold the pediatric dose based upon AUC comparisons). <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">Synovitis</span> and articular cartilage lesions were observed at the 10 and 40 mg/kg dose levels (approximately 0.7-fold and 2.4-fold the pediatric dose, respectively, based on AUC comparisons). Articular cartilage gross pathology and histopathology persisted to the end of the 18-week recovery period for those dogs from the 10 and 40 mg/kg/day dose levels.<br><br>When tested in a mouse ear <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> bioassay, levofloxacin exhibited <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> similar in magnitude to ofloxacin, but less <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> than other quinolones.<br><br>While <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> has been observed in some intravenous rat studies, urinary crystals are not formed in the bladder, being present only after micturition and are not associated with <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>.<br><br>In mice, the CNS stimulatory effect of quinolones is enhanced by concomitant administration of non-steroidal anti-inflammatory drugs.<br><br>In dogs, levofloxacin administered at 6 mg/kg or higher by rapid intravenous injection produced hypotensive effects. These effects were considered to be related to histamine release.<br><span class="Italics"><br>In vitro</span> and <span class="Italics">in vivo</span> studies in animals indicate that levofloxacin is neither an enzyme inducer nor inhibitor in the human therapeutic plasma concentration range; therefore, no drug metabolizing enzyme-related interactions with other drugs or agents are anticipated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-14.1"></a><p></p>
<h2>14.1	<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span> </h2>
<p class="First"><br>Adult patients with clinically and radiologically documented <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> were enrolled in a multicenter, randomized, open-label study comparing intravenous levofloxacin (750 mg once daily) followed by oral levofloxacin (750 mg once daily) for a total of 7 to 15 days to intravenous imipenem/cilastatin (500 to 1000 mg every 6 to 8 hours daily) followed by oral ciprofloxacin (750 mg every 12 hours daily) for a total of 7 to 15 days. Levofloxacin-treated patients received an average of 7 days of intravenous therapy (range: 1 to 16 days); comparator-treated patients received an average of 8 days of intravenous therapy (range: 1 to 19 days).<br><br>Overall, in the clinically and microbiologically evaluable population, adjunctive therapy was empirically initiated at study entry in 56 of 93 (60.2%) patients in the levofloxacin <span class="Sup"></span>arm and 53 of 94 (56.4%) patients in the comparator arm. The average duration of adjunctive therapy was 7 days in the levofloxacin arm and 7 days in the comparator. In clinically and microbiologically evaluable patients with documented <span class="Italics">Pseudomonas aeruginosa</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, 15 of 17 (88.2%) received ceftazidime (N=11) or piperacillin/tazobactam (N=4) in the levofloxacin arm and 16 of 17 (94.1%) received an aminoglycoside in the comparator arm. Overall, in clinically and microbiologically evaluable patients, vancomycin was added to the treatment regimen of 37 of 93 (39.8%) patients in the levofloxacin arm and 28 of 94 (29.8%) patients in the comparator arm for suspected methicillin-resistant <span class="Italics">S. aureus </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.<br><br>Clinical success rates in clinically and microbiologically evaluable patients at the posttherapy visit (primary study endpoint assessed on day 3 to 15 after completing therapy) were 58.1% for levofloxacin and 60.6% for comparator. The 95% CI for the difference of response rates (levofloxacin minus comparator) was [-17.2, 12]. The microbiological eradication rates at the posttherapy visit were 66.7% for levofloxacin and 60.6% for comparator. The 95% CI for the difference of eradication rates (levofloxacin minus comparator) was [-8.3, 20.3]. Clinical success and microbiological eradication rates by pathogen are detailed in Table 11.<br></p>
<a name="id2dd6f31-4d5d-4fb1-8461-83a2c7f6782f"></a><table border="0" cellpadding="0" cellspacing="0" width="492">
<caption><span>Table 11: Clinical Success Rates and Bacteriological Eradication Rates (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span>) 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Pathogen</th>
<th class="Lrule Rrule Toprule" align="center">N </th>
<th class="Lrule Rrule Toprule" align="center">Levofloxacin No. (%) of <br>Patients Microbiologic/<br>Clinical Outcomes</th>
<th class="Lrule Rrule Toprule" align="center">N </th>
<th class="Lrule Rrule Toprule" align="center">Imipenem/Cilastatin No. (%) of <br>Patients Microbiologic/<br>Clinical Outcomes</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a </span>Methicillin-susceptible <span class="Italics">S. aureus </span><br><span class="Sup">b </span>See above text for use of combination therapy<br><span class="Sup">c </span>The observed differences in rates for the clinical and microbiological outcomes may reflect other factors that were not accounted for in the study <br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">   MSSA<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">21<br>
</td>
<td class="Rrule" align="center" valign="top">14 (66.7)/13 (61.9)<br>
</td>
<td class="Rrule" align="center" valign="top">19<br>
</td>
<td class="Rrule" align="center" valign="top">13 (68.4)/15 (78.9)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   P. aeruginosa<span class="Sup">b</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
<td class="Rrule" align="center" valign="top">10 (58.8)/11 (64.7)<br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
<td class="Rrule" align="center" valign="top">5 (29.4)/7 (41.2)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   S. marcescens </span><br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
<td class="Rrule" align="center" valign="top">9 (81.8)/7 (63.6)<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">2 (28.6)/3 (42.9)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   E. coli </span><br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
<td class="Rrule" align="center" valign="top">10 (83.3)/7 (58.3)<br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
<td class="Rrule" align="center" valign="top">7 (63.6)/8 (72.7)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   K. pneumoniae<span class="Sup">c </span></span><br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
<td class="Rrule" align="center" valign="top">9 (81.8)/5 (45.5)<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">6 (85.7)/3 (42.9)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   H. influenzae </span><br>
</td>
<td class="Rrule" align="center" valign="top">16<br>
</td>
<td class="Rrule" align="center" valign="top">13 (81.3)/10 (62.5)<br>
</td>
<td class="Rrule" align="center" valign="top">15<br>
</td>
<td class="Rrule" align="center" valign="top">14 (93.3)/11 (73.3)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   S. pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">3 (75)/3 (75)<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">5 (71.4)/4 (57.1)<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.4"></a><a name="section-14.2"></a><p></p>
<h2>14.2	Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 7 to 14 day Treatment Regimen </h2>
<p class="First"><br>Adult inpatients and outpatients with a diagnosis of community-acquired bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> were evaluated in 2 pivotal clinical studies. In the first study, 590 patients were enrolled in a prospective, multi-center, unblinded randomized trial comparing levofloxacin 500 mg once daily orally or intravenously for 7 to 14 days to ceftriaxone 1 to 2 grams intravenously once or in equally divided doses twice daily followed by cefuroxime axetil 500 mg orally twice daily for a total of 7 to 14 days. Patients assigned to treatment with the control regimen were allowed to receive erythromycin (or doxycycline if intolerant of erythromycin) if an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> due to atypical pathogens was suspected or proven. Clinical and microbiologic evaluations were performed during treatment, 5 to 7 days posttherapy, and 3 to 4 weeks posttherapy. Clinical success (cure plus improvement) with levofloxacin <span class="Sup"></span>at 5 to 7 days posttherapy, the primary efficacy variable in this study, was superior (95%) to the control group (83%). The 95% CI for the difference of response rates (levofloxacin <span class="Sup"></span>minus comparator) was [-6, 19]. In the second study, 264 patients were enrolled in a prospective, multi-center, non-comparative trial of 500 mg levofloxacin administered orally or intravenously once daily for 7 to 14 days. Clinical success for clinically evaluable patients was 93%. For both studies, the clinical success rate in patients with <span class="product-label-link" type="condition" conceptid="4050869" conceptname="Atypical pneumonia">atypical pneumonia</span> due to <span class="Italics">Chlamydophila pneumoniae, Mycoplasma pneumoniae</span>, and <span class="Italics">Legionella pneumophila</span> were 96%, 96%, and 70%, respectively. Microbiologic eradication rates across both studies are presented in Table 12.<br></p>
<a name="i60fe3125-1175-402f-82e3-049bd6579c43"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 12: Bacteriological Eradication Rates Across 2 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> Clinical Studies 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Pathogen</th>
<th class="Lrule Rrule Toprule" align="center">No. Pathogens </th>
<th class="Lrule Rrule Toprule" align="center">Bacteriological<br>Eradication Rate (%) </th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   H. influenzae</span><br>
</td>
<td class="Rrule" align="center" valign="top">55<br>
</td>
<td class="Rrule" align="center" valign="top">98<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   S. pneumoniae</span><br>
</td>
<td class="Rrule" align="center" valign="top">83<br>
</td>
<td class="Rrule" align="center" valign="top">95<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   S. aureus</span><br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
<td class="Rrule" align="center" valign="top">88<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   M. catarrhalis</span><br>
</td>
<td class="Rrule" align="center" valign="top">18<br>
</td>
<td class="Rrule" align="center" valign="top">94<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   H. parainfluenzae </span><br>
</td>
<td class="Rrule" align="center" valign="top">19<br>
</td>
<td class="Rrule" align="center" valign="top">95<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   K. pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">100<br>
</td>
</tr>
</tbody>
</table>
<p><br><span class="Bold">Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> Due to Multi-Drug Resistant <span class="Italics">Streptococcus pneumoniae</span><br></span><br>Levofloxacin was effective for the treatment of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> caused by multi-drug resistant <span class="Italics">Streptococcus pneumoniae </span>(MDRSP). MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2<span class="Sup">nd </span>generation cephalosporins (e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole). Of 40 microbiologically evaluable patients with MDRSP isolates, 38 patients (95%) achieved clinical and bacteriologic success at post-therapy. The clinical and bacterial success rates are shown in Table 13.</p>
<a name="i1c47dfb4-c1c5-4874-8764-322ea9c365d6"></a><table border="0" cellpadding="0" cellspacing="0" width="588">
<caption><span>Table 13: Clinical and Bacterial Success Rates for Levofloxacin-Treated MDRSP in <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> Patients (Population Valid for Efficacy) 
			</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" rowspan="2">Screening Susceptibility</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Clinical Success</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Bacteriological Success<span class="Sup">c</span>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">n/N<span class="Sup">a</span>
</th>
<th class="Lrule Rrule Toprule" align="center">%</th>
<th class="Lrule Rrule Toprule" align="center">n/N<span class="Sup">b</span>
</th>
<th class="Lrule Rrule Toprule" align="center">%</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a </span>n=the number of microbiologically evaluable patients who were clinical successes; N=number of microbiologically evaluable patients in the designated resistance group.<br><span class="Sup">b </span>n=the number of MDRSP isolates eradicated or presumed eradicated in microbiologically evaluable patients; N=number of MDRSP isolates in a designated resistance group.<br><span class="Sup">c </span>One patient had a respiratory isolate that was resistant to tetracycline, cefuroxime, macrolides and TMP/SMX and intermediate to penicillin and a blood isolate that was intermediate to penicillin and cefuroxime and resistant to the other classes. The patient is included in the database based on respiratory isolate.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Penicillin-resistant </span><br>
</td>
<td class="Rrule" align="center" valign="top">16/17<br>
</td>
<td class="Rrule" align="center" valign="top">94.1<br>
</td>
<td class="Rrule" align="center" valign="top">16/17<br>
</td>
<td class="Rrule" align="center" valign="top">94.1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   2<span class="Sup">nd</span> generation Cephalosporin resistant </span><br>
</td>
<td class="Rrule" align="center" valign="top">31/32<br>
</td>
<td class="Rrule" align="center" valign="top">96.9<br>
</td>
<td class="Rrule" align="center" valign="top">31/32<br>
</td>
<td class="Rrule" align="center" valign="top">96.9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Macrolide-resistant </span><br>
</td>
<td class="Rrule" align="center" valign="top">28/29<br>
</td>
<td class="Rrule" align="center" valign="top">96.6<br>
</td>
<td class="Rrule" align="center" valign="top">28/29<br>
</td>
<td class="Rrule" align="center" valign="top">96.6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Trimethoprim/Sulfamethoxazole resistant </span><br>
</td>
<td class="Rrule" align="center" valign="top">17/19<br>
</td>
<td class="Rrule" align="center" valign="top">89.5<br>
</td>
<td class="Rrule" align="center" valign="top">17/19<br>
</td>
<td class="Rrule" align="center" valign="top">89.5<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Tetracycline-resistant </span><br>
</td>
<td class="Rrule" align="center" valign="top">12/12<br>
</td>
<td class="Rrule" align="center" valign="top">100<br>
</td>
<td class="Rrule" align="center" valign="top">12/12<br>
</td>
<td class="Rrule" align="center" valign="top">100<br>
</td>
</tr>
</tbody>
</table>
<p><br>Not all isolates were resistant to all antimicrobial classes tested. Success and eradication rates are summarized in Table 14.<br></p>
<a name="i1206ca3a-ce11-42e2-8d3a-4d8a86df0a09"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 14: Clinical Success and Bacteriologic Eradication Rates for Resistant Streptococcus pneumoniae (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span>)  
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">Type of Resistance</th>
<th class="Lrule Rrule Toprule" align="center">Clinical Success </th>
<th class="Lrule Rrule Toprule" align="center">Bacteriologic Eradication </th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">   Resistant to 2 antibacterials <br>
</td>
<td class="Rrule" align="center" valign="top">17/18 (94.4%)<br>
</td>
<td class="Rrule" align="center" valign="top">17/18 (94.4%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Resistant to 3 antibacterials <br>
</td>
<td class="Rrule" align="center" valign="top">14/15 (93.3%)<br>
</td>
<td class="Rrule" align="center" valign="top">14/15 (93.3%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Resistant to 4 antibacterials <br>
</td>
<td class="Rrule" align="center" valign="top">7/7 (100%)<br>
</td>
<td class="Rrule" align="center" valign="top">7/7 (100%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Resistant to 5 antibacterials <br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span> with MDRSP <br>
</td>
<td class="Rrule" align="center" valign="top">8/9 (89%)<br>
</td>
<td class="Rrule" align="center" valign="top">8/9 (89%)<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.5"></a><a name="section-14.3"></a><p></p>
<h2>14.3	Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 5-day Treatment Regimen </h2>
<p class="First"><br>To evaluate the safety and efficacy of the higher dose and shorter course of levofloxacin, 528 outpatient and hospitalized adults with clinically and radiologically determined mild to severe community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> were evaluated in a double-blind, randomized, prospective, multicenter study comparing levofloxacin 750 mg, IV or orally, every day for five days or levofloxacin 500 mg IV or orally, every day for 10 days.<br><br>Clinical success rates (cure plus improvement) in the clinically evaluable population were 90.9% in the levofloxacin 750 mg group and 91.1% in the levofloxacin 500 mg group. The 95% CI for the difference of response rates (levofloxacin 750 minus levofloxacin <span class="Sup"></span>500) was [-5.9, 5.4]. In the clinically evaluable population (31 to 38 days after enrollment) <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> was observed in 7 out of 151 patients in the levofloxacin 750 mg group and 2 out of 147 patients in the levofloxacin 500 mg group. Given the small numbers observed, the significance of this finding cannot be determined statistically. The microbiological efficacy of the 5-day regimen was documented for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> listed in Table 15.<br></p>
<a name="i3b8fb031-f973-4489-8869-3affdbbfcc3f"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 15: Bacteriological Eradication Rates (Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>) 
			</span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics">S. pneumoniae</span><br>
</td>
<td class="Rrule" align="center" valign="top">19/20 (95%) <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   Haemophilus influenzae</span><br>
</td>
<td class="Rrule" align="center" valign="top">12/12 (100%) <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   Haemophilus parainfluenzae</span><br>
</td>
<td class="Rrule" align="center" valign="top">10/10 (100%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   Mycoplasma pneumoniae</span><br>
</td>
<td class="Rrule" align="center" valign="top">26/27 (96%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   Chlamydophila pneumoniae</span><br>
</td>
<td class="Rrule" align="center" valign="top">13/15 (87%) <br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.6"></a><a name="section-14.4"></a><p></p>
<h2>14.4	Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>: 5-day and 10 to 14 day Treatment Regimens </h2>
<p class="First"><br>Levofloxacin is approved for the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> (ABS) using either 750 mg by mouth x 5 days or 500 mg by mouth once daily x 10 to 14 days. To evaluate the safety and efficacy of a high dose short course of levofloxacin, 780 outpatient adults with clinically and radiologically determined acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> were evaluated in a double-blind, randomized, prospective, multicenter study comparing levofloxacin 750 mg by mouth once daily for five days to levofloxacin 500 mg by mouth once daily for 10 days.<br><br>Clinical success rates (defined as complete or partial resolution of the pre-treatment signs and symptoms of ABS to such an extent that no further antibiotic treatment was deemed necessary) in the microbiologically evaluable population were 91.4% (139/152) in the levofloxacin 750 mg group and 88.6% (132/149) in the levofloxacin 500 mg group at the test-of-cure (TOC) visit (95% CI [-4.2, 10] for levofloxacin 750 mg minus levofloxacin <span class="Sup"></span>500 mg).<br><br>Rates of clinical success by pathogen in the microbiologically evaluable population who had specimens obtained by antral tap at study entry showed comparable results for the five- and ten-day regimens at the test-of-cure visit 22 days post treatment.<br></p>
<a name="ia535f8b6-637e-4757-8836-9cfbcd737f2f"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 16: Clinical Success Rate by Pathogen at the TOC in Microbiologically Evaluable Subjects Who Underwent Antral Puncture (Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>) 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Pathogen </th>
<th class="Lrule Rrule Toprule" align="center">Levofloxacin 750 mg x 5 days </th>
<th class="Lrule Rrule Toprule" align="center">Levofloxacin 500 mg x 10 days </th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="3">* Note: Forty percent of the subjects in this trial had specimens obtained by sinus endoscopy. The efficacy data for subjects whose specimen was obtained endoscopically were comparable to those presented in the above table.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   Streptococcus pneumoniae* </span><br>
</td>
<td class="Rrule" align="center" valign="top">25/27 (92.6%)<br>
</td>
<td class="Rrule" align="center" valign="top">26/27 (96.3%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   Haemophilus influenzae* </span><br>
</td>
<td class="Rrule" align="center" valign="top">19/21 (90.5%)<br>
</td>
<td class="Rrule" align="center" valign="top">25/27 (92.6%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   Moraxella catarrhalis* </span><br>
</td>
<td class="Rrule" align="center" valign="top">10/11 (90.9%)<br>
</td>
<td class="Rrule" align="center" valign="top">13/13 (100%)<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.7"></a><a name="section-14.5"></a><p></p>
<h2>14.5 	Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </h2>
<p class="First"><br>Three hundred ninety-nine patients were enrolled in an open-label, randomized, comparative study for complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The patients were randomized to receive either levofloxacin 750 mg once daily (IV followed by oral), or an approved comparator for a median of 10 ± 4.7 days. As is expected in complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, surgical procedures were performed in the levofloxacin and comparator groups. Surgery (incision and drainage or debridement) was performed on 45% of the levofloxacin-treated patients and 44% of the comparator-treated patients, either shortly before or during antibiotic treatment and formed an integral part of therapy for this indication.<br><br>Among those who could be evaluated clinically 2 to 5 days after completion of study drug, overall success rates (improved or cured) were 116/138 (84.1%) for patients treated with levofloxacin and 106/132 (80.3%) for patients treated with the comparator.<br><br>Success rates varied with the type of diagnosis ranging from 68% in patients with infected <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> to 90% in patients with infected <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>. These rates were equivalent to those seen with comparator drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.8"></a><a name="section-14.6"></a><p></p>
<h2>14.6 	Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span> </h2>
<p class="First"><br>Adult patients with a clinical diagnosis of <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span> and microbiological culture results from urine sample collected after prostatic massage (VB<span class="Sub">3</span>) or expressed prostatic secretion (EPS) specimens obtained via the Meares-Stamey procedure were enrolled in a multicenter, randomized, double-blind study comparing oral levofloxacin 500 mg, once daily for a total of 28 days to oral ciprofloxacin 500 mg, twice daily for a total of 28 days. The primary efficacy endpoint was microbiologic efficacy in microbiologically evaluable patients. A total of 136 and 125 microbiologically evaluable patients were enrolled in the levofloxacin and ciprofloxacin groups, respectively. The microbiologic eradication rate by patient <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at 5 to 18 days after completion of therapy was 75% in the levofloxacin group and 76.8% in the ciprofloxacin group (95% CI [-12.58, 8.98] for levofloxacin minus ciprofloxacin). The overall eradication rates for pathogens of interest are presented in Table 17. <br></p>
<a name="ic06236d1-84b9-4457-8492-45dc9c26d923"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 17: Bacteriological Eradication Rates (Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span>) 
			</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" rowspan="2">Pathogen</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Levofloxacin (N = 136)</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Ciprofloxacin (N = 125)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">N </th>
<th class="Lrule Rrule Toprule" align="center">Eradication</th>
<th class="Lrule Rrule Toprule" align="center">N </th>
<th class="Lrule Rrule Toprule" align="center">Eradication</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="5">* Eradication rates shown are for patients who had a sole pathogen only; mixed cultures were excluded. <br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   E. coli </span><br>
</td>
<td class="Rrule" align="center" valign="top">15 <br>
</td>
<td class="Rrule" align="center" valign="top">14 (93.3%)<br>
</td>
<td class="Rrule" align="center" valign="top">11 <br>
</td>
<td class="Rrule" align="center" valign="top">9 (81.8%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   E. faecalis </span><br>
</td>
<td class="Rrule" align="center" valign="top">54 <br>
</td>
<td class="Rrule" align="center" valign="top">39 (72.2%)<br>
</td>
<td class="Rrule" align="center" valign="top">44 <br>
</td>
<td class="Rrule" align="center" valign="top">33 (75%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   S. epidermidis* </span><br>
</td>
<td class="Rrule" align="center" valign="top">11 <br>
</td>
<td class="Rrule" align="center" valign="top">9 (81.8%)<br>
</td>
<td class="Rrule" align="center" valign="top">14 <br>
</td>
<td class="Rrule" align="center" valign="top">11 (78.6%)<br>
</td>
</tr>
</tbody>
</table>
<p> rates for <span class="Italics">S. epidermidis </span>when found with other co-pathogens are consistent with rates seen in pure isolates.<br><br>Clinical success (cure + improvement with no need for further antibiotic therapy) rates in microbiologically evaluable population 5 to 18 days after completion of therapy were 75% for levofloxacin-treated patients and 72.8% for ciprofloxacin-treated patients (95% CI [-8.87, 13.27] for levofloxacin minus ciprofloxacin). Clinical long-term success (24 to 45 days after completion of therapy) rates were 66.7% for the levofloxacin-treated patients and 76.9% for the ciprofloxacin-treated patients (95% CI [-23.4, 2.89] for levofloxacin minus ciprofloxacin).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.9"></a><a name="section-14.7"></a><p></p>
<h2>14.7	Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 5-day Treatment Regimen </h2>
<p class="First"><br>To evaluate the safety and efficacy of the higher dose and shorter course of levofloxacin, 1109 patients with cUTI and AP were enrolled in a randomized, double-blind, multicenter clinical trial conducted in the U.S. from November 2004 to April 2006 comparing levofloxacin 750 mg IV or orally once daily for 5 days (546 patients) with ciprofloxacin 400 mg IV or 500 mg orally twice daily for 10 days (563 patients). Patients with AP complicated by underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal diseases</span> or conditions such as complete obstruction, surgery, transplantation, concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or congenital malformation were excluded. Efficacy was measured by bacteriologic eradication of the baseline organism(s) at the post-therapy visit in patients with a pathogen identified at baseline. The post-therapy (test-of-cure) visit occurred 10 to 14 days after the last active dose of levofloxacin and 5 to 9 days after the last dose of active ciprofloxacin.<br><br>The bacteriologic cure rates overall for levofloxacin and control at the test-of-cure (TOC) visit for the group of all patients with a documented pathogen at baseline (modified intent to treat or mITT) and the group of patients in the mITT population who closely followed the protocol (Microbiologically Evaluable) are summarized in Table 18.</p>
<a name="ie68302ee-bbca-4f68-8dad-f48dc5d39545"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 18: Bacteriological Eradication at Test-of-Cure  
			</span></caption>
<tfoot><tr class="First Last"><td colspan="6">
<span class="Sup">a </span>The mITT population included patients who received study medication and who had a positive (≥10<span class="Sup">5</span> CFU/mL) urine culture with no more than 2 uropathogens at baseline. Patients with missing response were counted as failures in this analysis. <br><span class="Sup">b </span>The Microbiologically Evaluable population included patients with a confirmed diagnosis of cUTI or AP, a causative organism(s) at baseline present at ≥ 10<span class="Sup">5 </span>CFU/mL, a valid test-of-cure urine culture, no pathogen isolated from blood resistant to study drug, no premature discontinuation or loss to follow-up, and compliance with treatment (among other criteria).<br>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" rowspan="2" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Levofloxacin<br></span>750 mg orally or<br>IV once daily<br>for 5 days<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Ciprofloxacin<br></span>400 mg IV/500 mg <br>orally twice daily<br>for 10 days<br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Overall Difference<br>[95% CI]</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">n/N<br>
</td>
<td class="Rrule" align="center" valign="top">%<br>
</td>
<td class="Rrule" align="center" valign="top">n/N<br>
</td>
<td class="Rrule" align="center" valign="top">%<br>
</td>
<td class="Rrule" align="center" valign="top">Levofloxacin-<br>Ciprofloxacin<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="6" valign="top">
<span class="Bold">mITT Population<span class="Sup">a</span></span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Overall (cUTI or AP) <br>
</td>
<td class="Rrule" align="center" valign="top">252/333 <br>
</td>
<td class="Rrule" align="center" valign="top">75.7 <br>
</td>
<td class="Rrule" align="center" valign="top">239/318 <br>
</td>
<td class="Rrule" align="center" valign="top">75.2 <br>
</td>
<td class="Rrule" align="center" valign="top">0.5 (-6.1, 7.1)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   cUTI <br>
</td>
<td class="Rrule" align="center" valign="top">168/230 <br>
</td>
<td class="Rrule" align="center" valign="top">73 <br>
</td>
<td class="Rrule" align="center" valign="top">157/213 <br>
</td>
<td class="Rrule" align="center" valign="top">73.7 <br>
</td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   AP <br>
</td>
<td class="Rrule" align="center" valign="top">84/103 <br>
</td>
<td class="Rrule" align="center" valign="top">81.6 <br>
</td>
<td class="Rrule" align="center" valign="top">82/105 <br>
</td>
<td class="Rrule" align="center" valign="top">78.1 <br>
</td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="6" valign="top">
<span class="Bold">Microbiologically Evaluable Population<span class="Sup">b</span></span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Overall (cUTI or AP) <br>
</td>
<td class="Rrule" align="center" valign="top">228/265 <br>
</td>
<td class="Rrule" align="center" valign="top">86 <br>
</td>
<td class="Rrule" align="center" valign="top">215/241<br>
</td>
<td class="Rrule" align="center" valign="top">89.2 <br>
</td>
<td class="Rrule" align="center" valign="top">-3.2 [-8.9, 2.5]<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   cUTI <br>
</td>
<td class="Rrule" align="center" valign="top">154/185 <br>
</td>
<td class="Rrule" align="center" valign="top">83.2 <br>
</td>
<td class="Rrule" align="center" valign="top">144/165 <br>
</td>
<td class="Rrule" align="center" valign="top">87.3 <br>
</td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">   AP <br>
</td>
<td class="Rrule" align="center" valign="top">74/80 <br>
</td>
<td class="Rrule" align="center" valign="top">92.5 <br>
</td>
<td class="Rrule" align="center" valign="top">71/76 <br>
</td>
<td class="Rrule" align="center" valign="top">93.4 <br>
</td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
</tbody>
</table>
<p><br>Microbiologic eradication rates in the Microbiologically Evaluable population at TOC for individual pathogens recovered from patients randomized to levofloxacin treatment are presented in Table 19.<br></p>
<a name="i4fd21ecc-a7d0-4f99-865e-640d22a06688"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 19: Bacteriological Eradication Rates for Individual Pathogens Recovered From Patients Randomized to Levofloxacin 750 mg QD for 5 Days Treatment  
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Pathogen</th>
<th class="Lrule Rrule Toprule" align="center">Bacteriological<br>Eradication Rate (n/N) </th>
<th class="Lrule Rrule Toprule" align="center">%</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="3">* The predominant organism isolated from patients with AP was <span class="Italics">E. coli</span>: 91% (63/69) eradication in AP and 89% (92/103) in patients with cUTI.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   Escherichia coli* </span><br>
</td>
<td class="Rrule" align="center" valign="top">155/172<br>
</td>
<td class="Rrule" align="center" valign="top">90 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   Klebsiella pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">20/23<br>
</td>
<td class="Rrule" align="center" valign="top">87 <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">   Proteus mirabilis </span><br>
</td>
<td class="Rrule" align="center" valign="top">12/12<br>
</td>
<td class="Rrule" align="center" valign="top">100 <br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.10"></a><a name="section-14.8"></a><p></p>
<h2>14.8	Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 10-day Treatment Regimen</h2>
<p class="First"><br>To evaluate the safety and efficacy of the 250 mg dose, 10 day regimen of levofloxacin, 567 patients with uncomplicated UTI, mild-to-moderate cUTI, and mild-to-moderate AP were enrolled in a randomized, double-blind, multicenter clinical trial conducted in the U.S. from June 1993 to January 1995 comparing levofloxacin 250 mg orally once daily for 10 days (285 patients) with ciprofloxacin 500 mg orally twice daily for 10 days (282 patients). Patients with a resistant pathogen, recurrent UTI, women over age 55 years, and with an indwelling catheter were initially excluded, prior to protocol amendment which took place after 30% of enrollment. Microbiological efficacy was measured by bacteriologic eradication of the baseline organism(s) at 1 to 12 days post-therapy in patients with a pathogen identified at baseline.<br><br>The bacteriologic cure rates overall for levofloxacin and control at the test-of-cure (TOC) visit for the group of all patients with a documented pathogen at baseline (modified intent to treat or mITT) and the group of patients in the mITT population who closely followed the protocol (Microbiologically Evaluable) are summarized in Table 20.</p>
<a name="i6627ed17-d3c6-4bcd-8b1f-a897b15cba18"></a><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 20: Bacteriological Eradication Overall (cUTI or AP) at Test-Of-Cure<span class="Sup">a</span></span></caption>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span> 1 to 9 days posttherapy for 30% of subjects enrolled prior to a protocol amendment; 5 to 12 days posttherapy for 70% of subjects.<br><span class="Sup">b </span>The mITT population included patients who had a pathogen isolated at baseline. Patients with missing response were counted as failures in this analysis. <br><span class="Sup">c </span>The Microbiologically Evaluable population included mITT patients who met protocol-specified evaluability criteria.<br>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" rowspan="2" valign="top"><br></td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Levofloxacin<br></span>250 mg once daily <br>for 10 days<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Ciprofloxacin<br></span>500 mg twice daily <br>for 10 days<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">n/N <br>
</td>
<td class="Rrule" align="center" valign="top">% <br>
</td>
<td class="Rrule" align="center" valign="top">n/N <br>
</td>
<td class="Rrule" align="center" valign="top">% <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   mITT Population<span class="Sup">b</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">174/209 <br>
</td>
<td class="Rrule" align="center" valign="top">83.3 <br>
</td>
<td class="Rrule" align="center" valign="top">184/219 <br>
</td>
<td class="Rrule" align="center" valign="top">84 <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Microbiologically Evaluable Population<span class="Sup">c</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">164/177 <br>
</td>
<td class="Rrule" align="center" valign="top">92.7 <br>
</td>
<td class="Rrule" align="center" valign="top">159/171 <br>
</td>
<td class="Rrule" align="center" valign="top">93 <br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.11"></a><a name="section-14.9"></a><p></p>
<h2>14.9	Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure) </h2>
<p class="First"><br>The effectiveness of levofloxacin for this indication is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>. The mean plasma concentrations of levofloxacin associated with a statistically significant improvement in survival over placebo in the rhesus monkey model of inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> are reached or exceeded in adult and pediatric patients receiving the recommended oral and intravenous dosage regimens <span class="Italics">[see <a href="#Section_1.14">Indications and Usage (1.13)</a>; <a href="#Section_2.1">Dosage and Administration (2.1</a>, <a href="#Section_2.3">2.2)</a>].</span><br><br>Levofloxacin pharmacokinetics have been evaluated in adult and pediatric patients. The mean (± SD) steady state peak plasma concentration in human adults receiving 500 mg orally or intravenously once daily is 5.7 ± 1.4 and 6.4 ± 0.8 mcg/mL, respectively; and the corresponding total plasma exposure (AUC<span class="Sub">0-24</span>) is 47.5 ± 6.7 and  54.6 ± 11.1 mcg•h/mL, respectively. The predicted steady-state pharmacokinetic parameters in pediatric patients ranging in age from 6 months to 17 years receiving 8 mg/kg orally every 12 hours (not to exceed 250 mg per dose) were calculated to be comparable to those observed in adults receiving 500 mg orally once daily <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.<br><br>In adults, the safety of levofloxacin for treatment durations of up to 28 days is well characterized. However, information pertaining to extended use at 500 mg daily up to 60 days is limited. Prolonged levofloxacin therapy in adults should only be used when the benefit outweighs the risk.<br><br>In pediatric patients, the safety of levofloxacin for treatment durations of more than 14 days has not been studied. An increased incidence of musculoskeletal adverse events (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, tendinopathy, gait abnormality) compared to controls has been observed in clinical studies with treatment duration of up to 14 days. Long-term safety data, including effects on cartilage, following the administration of levofloxacin to pediatric patients is limited <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.10)</a>, <a href="#Section_8.4">Use in Specific Populations (8.4)</a>].</span><br><br>A placebo-controlled animal study in rhesus monkeys exposed to an inhaled mean dose of 49 LD<span class="Sub">50</span> (~2.7 x 10<span class="Sup">6</span>) spores (range 17 to 118 LD<span class="Sub">50</span>) of <span class="Italics">B. anthracis</span> (Ames <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>) was conducted. The minimal inhibitory concentration (MIC) of levofloxacin for the <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> used in this study was 0.125 mcg/mL. In the animals studied, mean plasma concentrations of levofloxacin achieved at expected T<span class="Sub">max</span> (1 hour post-dose) following oral dosing to steady state ranged from 2.79 to 4.87 mcg/mL. Steady state trough concentrations at 24 hours post-dose ranged from 0.107 to 0.164 mcg/mL. Mean (SD) steady state AUC<span class="Sub">0-24</span> was 33.4 ± 3.2 mcg•h/mL (range 30.4 to 36 mcg•h/mL). Mortality due to <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> for animals that received a 30 day regimen of oral levofloxacin beginning 24 hrs post exposure was significantly lower (1/10), compared to the placebo group (9/10) [P=0.0011, 2-sided Fisher’s Exact Test]. The one levofloxacin treated animal that died of <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> did so following the 30-day drug administration period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.16"></a><a name="section-14.10"></a><p></p>
<h2>14.10  <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span></h2>
<p class="First"><br>Efficacy studies of levofloxacin <span class="Sup"></span>could not be conducted in humans with pneumonic <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals.<br><br>The mean plasma concentrations of levofloxacin <span class="Sup"></span>associated with a statistically significant improvement in survival over placebo in an African green monkey model of pneumonic <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> are reached or exceeded in adult and pediatric patients receiving the recommended oral and intravenous dosage regimens <span class="Italics">[see <a href="#Section_1.14">Indications and Usage (1.14)</a></span>, <span class="Italics"><a href="#Section_2.1">Dosage and Administration (2.1)</a></span>, <span class="Italics"><a href="#Section_2.3">(2.2)</a>]</span>.<br><br>Levofloxacin pharmacokinetics have been evaluated in adult and pediatric patients. The mean (± SD) steady state peak plasma concentration in human adults receiving 500 mg orally or intravenously once daily is 5.7 ± 1.4 and 6.4 ± 0.8 mcg/mL, respectively; and the corresponding total plasma exposure (AUC<span class="Sub">0-24</span>) is 47.5 ± 6.7 and 54.6 ± 11.1 mcg.h/mL, respectively. The predicted steady-state pharmacokinetic parameters in pediatric patients ranging in age from 6 months to 17 years receiving 8 mg/kg orally every 12 hours (not to exceed 250 mg per dose) were calculated to be comparable to those observed in adults receiving 500 mg orally once daily <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.<br><br>A placebo-controlled animal study in African green monkeys exposed to an inhaled mean dose of 65 LD<span class="Sub">50</span> (range 3 to 145 LD<span class="Sub">50</span>) of <span class="Italics">Yersinia pestis </span>(CO92 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>) was conducted. The minimal inhibitory concentration (MIC) of levofloxacin for the <span class="Italics">Y. pestis </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> used in this study was 0.03 mcg/mL. Mean plasma concentrations of levofloxacin achieved at the end of a single 30-min infusion ranged from 2.84 to 3.5 mcg/mL in African green monkeys. Trough concentrations at 24 hours post-dose ranged from &lt;0.03 to 0.06 mcg/mL. Mean (SD) AUC<span class="Sub">0-24</span> was 11.9 (3.1) mcg.h/mL (range 9.5 to 16.86 mcg.h/mL). Animals were randomized to receive either a 10-day regimen of i.v. levofloxacin <span class="Sup"></span>or placebo beginning within 6 hrs of the onset of telemetered <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (≥ 39<span class="Sup">o</span>C for more than 1 hour). Mortality in the levofloxacin <span class="Sup"></span>group was significantly lower (1/17) compared to the placebo group (7/7) [p&lt;0.001, Fisher’s Exact Test; exact 95% confidence interval (-99.9%, -55.5%) for the difference in mortality]. One levofloxacin-treated animal was euthanized on Day 9 post-exposure to <span class="Italics">Y. pestis </span>due to a gastric complication; it had a blood culture positive for <span class="Italics">Y. pestis </span>on Day 3 and all subsequent daily blood cultures from Day 4 through Day 7 were negative.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_15"></a><a name="section-15"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Underline">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically</span>. Approved Standard – 9<span class="Sup">th </span>ed. CLSI Document M7-A9, CLSI, 950 West Valley Rd., Suite 2500, Wayne, PA, 2012.    </li>
<li>CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 22<span class="Sup">nd </span>Informational Supplement. CLSI Document M100 – S22, 2012.    </li>
<li>CLSI Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard – 11<span class="Sup">th </span>ed. CLSI M2-A11, 2012.</li>
<li>CLSI. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline – 2<span class="Sup">nd </span>ed. CLSI Document M45-A2, 2010. </li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-16"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_16.1"></a><a name="section-16.1"></a><p></p>
<h2>16.1	Levofloxacin Tablets</h2>
<p class="First"><br><span class="Bold"><br><br>Levofloxacin Tablets, 750 mg </span>are white capsule shaped, biconvex film-coated tablets, debossed with ‘11’ on one side and ‘T’ on the other side.<br><br>          Bottles of 5, 7, 10 and 20.<br><span class="Bold"><br>Store at</span> 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in well-closed containers.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-17"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<br><p class="First">See <span class="Italics"><span class="Italics"><span class="Italics"><span class="Italics"><a href="#Section_19">FDA-Approved Medication Guide (17.6)</a></span></span></span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-17.1"></a><p></p>
<h2>17.1	Antibacterial Resistance </h2>
<br><p class="First">Antibacterial drugs including levofloxacin should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When levofloxacin is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by levofloxacin <span class="Sup"></span>or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.2"></a><a name="section-17.2"></a><p></p>
<h2>17.2	Administration with Food, Fluids, and Concomitant Medications</h2>
<p class="First"><br>Patients should be informed that levofloxacin tablets may be taken with or without food. The tablet should be taken at the same time each day.<br><br>Patients should drink fluids liberally while taking levofloxacin to avoid formation of a highly concentrated urine and crystal formation in the urine.<br><br>Antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine should be taken at least two hours before or two hours after oral levofloxacin administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.3"></a><a name="section-17.3"></a><p></p>
<h2>17.3	Serious and Potentially Serious Adverse Reactions </h2>
<p class="First"><br>Patients should be informed of the following serious adverse reactions that have been associated with levofloxacin or other fluoroquinolone use:   <br></p>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">Tendon Disorders</span>:</span> Patients should contact their healthcare provider if they experience <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of a tendon, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or inability to use one of their joints; rest and refrain from exercise; and discontinue levofloxacin <span class="Sup"></span>treatment. <span class="Bold">The risk of severe <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> with fluoroquinolones is higher in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. </span>
</li>
<li>
<span class="Bold">Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span>:</span> Patients should inform their physician of any history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Patients should notify their physician if they experience any symptoms of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, including respiratory difficulties.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span> Patients should be informed that levofloxacin can cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, even following the first dose. Patients should discontinue the drug at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> or other <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, a rapid heartbeat, difficulty in swallowing or breathing, any <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> suggesting <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (e.g., <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, face, tightness of the throat, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>), or other symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.  </li>
<li>
<span class="Bold">Hepatotoxicity:</span> Severe hepatotoxicity (including acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and fatal events) has been reported in patients taking levofloxacin. Patients should inform their physician and be instructed to discontinue levofloxacin treatment immediately if they experience any signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> including: loss of appetite, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, yellowing of the skin and eyes, light colored bowel movements or dark colored urine.  </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported in patients taking fluoroquinolones, including levofloxacin. Patients should notify their physician before taking this drug if they have a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.  </li>
<li>
<span class="Bold">Neurologic Adverse Effects (e.g., <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>):</span> Patients should know how they react to levofloxacin before they operate an automobile or machinery or engage in other activities requiring mental alertness and coordination. Patients should notify their physician if persistent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> with or without <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> occurs. </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.  </li>
<li>
<span class="Bold">Peripheral Neuropathies:</span> If symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and/or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> develop, patients should discontinue treatment and contact their physician.  </li>
<li>
<span class="Bold">Prolongation of the QT Interval:</span> Patients should inform their physician of any personal or family history of QT prolongation or proarrhythmic conditions such as <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, or recent <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>; if they are taking any Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. Patients should notify their physicians if they have any symptoms of prolongation of the QT interval, including prolonged heart <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> or a <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span> in Pediatric Patients:</span> Parents should inform their child's physician if their child has a history of joint-related problems before taking this drug. Parents of pediatric patients should also notify their child's physician of any tendon or joint-related problems that occur during or following levofloxacin <span class="Sup"></span>therapy <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.10)</a> and <a href="#Section_8.4">Use in Specific Populations (8.4)</a>]. </span><span class="Italics"></span>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span>:</span> Patients should be advised that <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> has been reported in patients receiving fluoroquinolone antibiotics. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while taking fluoroquinolones. If patients need to be outdoors when taking fluoroquinolones, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. If a sunburn like reaction or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruption</span> occurs, patients should contact their physician. </li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.4"></a><a name="section-17.4"></a><p></p>
<h2>17.4	Drug Interactions with Insulin, Oral Hypoglycemic Agents, and Warfarin</h2>
<p class="First"><br>Patients should be informed that if they are diabetic and are being treated with insulin or an oral hypoglycemic agent and a <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reaction</span> occurs, they should discontinue levofloxacin and consult a physician.<br><br>Patients should be informed that concurrent administration of warfarin and levofloxacin <span class="Sup"></span>has been associated with increases of the International Normalized Ratio (INR) or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and clinical episodes of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients should notify their physician if they are taking warfarin, be monitored for evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and also have their anticoagulation tests closely monitored while taking warfarin concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.5"></a><a name="section-17.5"></a><p></p>
<h2>17.5  <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span> and <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> Studies</h2>
<p class="First"><br>Patients given levofloxacin <span class="Sup"></span>for these conditions should be informed that efficacy studies could not be conducted in humans for ethical and feasibility reasons. Therefore, approval for these conditions was based on efficacy studies conducted in animals.<br><br>Manufactured for:<br><span class="Bold">Aurobindo Pharma USA, Inc.</span><br>2400 Route 130 North<br>Dayton, NJ 08810<br><br>Manufactured by:<br><span class="Bold">Aurobindo Pharma Limited</span><br>Unit-VII (SEZ)<br>Mahaboob Nagar (Dt)<br>AP-509302, INDIA<br><br>Revised: 06/2012</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="Section_19"></a><a name="section-18"></a><p></p>
<h1>17.6	FDA-Approved Medication Guide</h1>
<p class="First"><br><span class="Bold">MEDICATION GUIDE</span><br><span class="Bold">Levofloxacin Tablets</span><br><br>Read this Medication Guide before you start taking levofloxacin tablets and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment.<br><br><span class="Bold">What is the most important information I should know about levofloxacin tablets?</span><br><br><span class="Bold">Levofloxacin tablets, a fluoroquinolone antibiotic, can cause serious side effects. Some of these serious side effects could result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span><span class="Bold">.<br><br></span>If you have any of the following serious side effects while you take levofloxacin tablets, get medical help right away. Talk with your healthcare provider about whether you should continue to take levofloxacin tablets.<br><span class="Bold"><br>1.  <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tendon (<span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>).</span><br></p>
<ul class="Disc"><li>
<span class="Bold">Tendon problems can happen in people of all ages who take levofloxacin tablets. </span>Tendons are tough cords of tissue that connect muscles to bones.</li></ul>
<p><br>Some tendon problems include <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, tears, and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of tendons including the back of the ankle (Achilles), shoulder, hand, or other tendon sites.<br></p>
<ul class="Disc">
<li>
<p class="First">The risk of getting tendon problems while you take levofloxacin tablets are higher if you:<span class="Bold"></span></p>
<ul class="Disc">
<li>are over 60 years of age</li>
<li>are taking steroids (corticosteroids) </li>
<li>have had a kidney, heart or lung transplant.   </li>
</ul>
</li>
<li>Tendon problems can happen in people who do not have the above risk factors when they take levofloxacin tablets. </li>
<li>Other reasons that can increase your risk of tendon problems can include:  <ul class="Disc">
<li>physical activity or exercise </li>
<li><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li>tendon problems in the past, such as in people with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA)   </li>
</ul>
</li>
<li>Call your healthcare provider right away at the first sign of <span class="product-label-link" type="condition" conceptid="4068332" conceptname="Tenalgia">tendon pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. Stop taking levofloxacin tablets until <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> has been ruled out by your healthcare provider. Avoid exercise and using the affected area.</li>
</ul>
<p><br>The most common area of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> is the Achilles tendon at the back of your ankle. This can also happen with other tendons. Talk to your healthcare provider about the risk of <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> with continued use of levofloxacin tablets. You may need a different antibiotic that is not a fluoroquinolone to treat your <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.<br></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> can happen while you are taking or after you have finished taking levofloxacin tablets. <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon ruptures</span> have happened up to several months after people have finished taking their fluoroquinolone.</li>
<li>Get medical help right away if you get any of the following signs or symptoms of a <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>:<ul class="Disc">
<li>hear or feel a snap or pop in a tendon area</li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> right after an injury in a tendon area</li>
<li>unable to move the affected area or bear weight </li>
</ul>
</li>
</ul>
<p><br><span class="Bold">2.  Worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> (a problem that causes <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>). </span>Fluoroquinolones like levofloxacin tablets may cause worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> symptoms, including <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and breathing problems. Call your healthcare provider right away if you have any worsening <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or breathing problems.<br></p>
<ul class="Disc"><li>See <span class="Bold">“What are the possible side effects of levofloxacin tablets??</span>
</li></ul>
<p><br><span class="Bold">What are levofloxacin tablets?</span><br><br>Levofloxacin tablets are a fluoroquinolone antibiotic medicine used in adults age 18 years or older to treat certain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by certain germs called bacteria. <br>These <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> include:<br></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span></li>
<li>community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></li>
<li>acute <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span></li>
<li>acute worsening of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span>, complicated and uncomplicated</li>
<li>chronic prostate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, complicated and uncomplicated</li>
<li><span class="product-label-link" type="condition" conceptid="192964" conceptname="Infectious disorder of kidney">acute kidney infection</span> (<span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>)</li>
<li>inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span></li>
<li><span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span></li>
</ul>
<p><br>Studies of levofloxacin tablets for use in the treatment of <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> and <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> were done in animals only, because <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> and <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> could not be studied in people.<br><br>Levofloxacin tablets are also used to treat children who are 6 months of age or older and may have breathed in <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> germs, have <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span>, or been exposed to <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span> germs.<br><br>It is not known if levofloxacin tablets are safe and effective in children under 6 months of age.<br><br>The safety and effectiveness in children treated with levofloxacin tablets for more than 14 days is not known.<br><br><span class="Bold">Who should not take levofloxacin tablets?</span><br><br><span class="Bold">Do not take levofloxacin tablets </span>if you have ever had a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to an antibiotic known as a fluoroquinolone, or if you are allergic to levofloxacin or any of the ingredients in levofloxacin tablets. See the end of this leaflet for a complete list of ingredients in levofloxacin tablets.<br><br><span class="Bold">What should I tell my healthcare provider before taking levofloxacin tablets?</span><br><br><span class="Bold">Before you take levofloxacin tablets</span><span class="Bold">, tell your healthcare provider if you:</span></p>
<ul class="Disc">
<li>have tendon problems</li>
<li>have a problem that causes <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> (<span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>)</li>
<li>have central nervous system problems such as <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>)</li>
<li>have nerve problems</li>
<li>have or anyone in your family has an irregular heartbeat, especially a condition called “QT prolongation?</li>
<li>have low <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>)</li>
<li>have bone problems</li>
<li>have joint problems including <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA)</li>
<li>have kidney problems. You may need a lower dose of levofloxacin tablets if your kidneys do not work well.</li>
<li>have liver problems</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or problems with low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>)</li>
<li>are pregnant or plan to become pregnant. It is not known if levofloxacin tablets will harm your unborn child.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if levofloxacin passes into your breast milk. You and your healthcare provider should decide if you will take levofloxacin tablets or breastfeed. You should not do both.</li>
</ul>
<p><br><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements.<br><br>Levofloxacin tablets and other medicines can affect each other causing side effects.<br><br>Especially tell your healthcare provider if you take: <br></p>
<ul class="Disc">
<li>a steroid medicine</li>
<li>an anti-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> medicine</li>
<li>a tricyclic antidepressant</li>
<li>a water pill (diuretic)</li>
<li>certain medicines may keep levofloxacin tablets from working correctly. Take levofloxacin tablets either 2 hours before or 2 hours after taking these medicines or supplements:<ul class="Disc">
<li>an antacid, multivitamin, or other medicines or supplements that have magnesium, aluminum, iron, or zinc</li>
<li>sucralfate (Carafate<span class="Sup">®</span>)</li>
<li>didanosine (Videx<span class="Sup">®</span>,Videx<span class="Sup">®</span>EC)  </li>
</ul>
</li>
<li>a blood thinner (warfarin, Coumadin, Jantoven)</li>
<li>an oral anti-<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine or insulin</li>
<li>an NSAID (Non-Steroidal Anti-Inflammatory Drug). Many common medicines for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief are NSAIDs. Taking an NSAID while you take levofloxacin tablets or other fluoroquinolones may increase your risk of central nervous system effects and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</li>
<li>theophylline (Theo-24<span class="Sup">®</span>, Elixophyllin<span class="Sup">®</span>, Theochron<span class="Sup">®</span>, Uniphyl<span class="Sup">®</span>, Theolair<span class="Sup">®</span>)</li>
<li>a medicine to control your heart rate or rhythm (antiarrhythmics)</li>
</ul>
<p><br>Ask your healthcare provider if you are not sure if any of your medicines are listed above. <br><br>Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.<span class="Bold"><br><br>How should I take levofloxacin tablets?</span></p>
<ul class="Disc">
<li>Take levofloxacin tablets exactly as your healthcare provider tells you to take them.    </li>
<li>Take levofloxacin tablets at about the same time each day.    </li>
<li>Drink plenty of fluids while you take levofloxacin tablets.    </li>
<li>Levofloxacin tablets can be taken with or without food.</li>
<li>If you miss a dose of levofloxacin tablets, take it as soon as you remember. Do not take more than 1 dose in 1 day.    </li>
<li>Do not skip any doses of levofloxacin tablets or stop taking them, even if you begin to feel better, until you finish your prescribed treatment unless:    <ul class="Disc">
<li>you have tendon problems. See <span class="Bold">“What is the most important information I should know about levofloxacin </span><span class="Bold">tablets??</span><span class="Bold">.</span>
</li>
<li>you have a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. See <span class="Bold">“What are the possible side effects of levofloxacin </span><span class="Bold">tablets??.</span>
</li>
<li>your healthcare provider tells you to stop taking levofloxacin tablets. </li>
</ul>
</li>
</ul>
<p><br>Taking all of your levofloxacin tablets doses will help make sure that all of the bacteria are killed. Taking all of your levofloxacin tablets doses will help you lower the chance that the bacteria will become resistant to levofloxacin tablets. If your <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> does not get better while you take levofloxacin tablets, it may mean that the bacteria causing your <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may be resistant to levofloxacin tablets. If your <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> does not get better, call your healthcare provider. If your <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> does not get better, levofloxacin tablets and other similar antibiotic medicines may not work for you in the future.<br></p>
<ul class="Disc"><li>If you take too much levofloxacin, call your healthcare provider or get medical help right away.</li></ul>
<p><br><span class="Bold">What should I avoid while taking levofloxacin tablets?</span><br></p>
<ul class="Disc">
<li>Levofloxacin tablets can make you feel dizzy and lightheaded. Do not drive, operate machinery, or do other activities that require mental alertness or coordination until you know how levofloxacin tablets affect you.</li>
<li>Avoid sunlamps, tanning beds, and try to limit your time in the sun. Levofloxacin tablets can make your skin sensitive to the sun (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>) and the light from sunlamps and tanning beds. You could get severe sunburn, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your skin. If you get any of these symptoms while you take levofloxacin tablets, call your healthcare provider right away. You should use a sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight. </li>
</ul>
<p><br><span class="Bold">What are the possible side effects of levofloxacin tablets?</span><br><br><span class="Bold">Levofloxacin tablets </span><span class="Bold">can cause serious side effects, including:</span><br></p>
<ul class="Disc">
<li>See “<span class="Bold">What is the most important information I should know about l</span><span class="Bold">evofloxacin tablets??</span>
</li>
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span>. </li>
</ul>
<p><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> can happen in people taking fluoroquinolones, including levofloxacin tablets, even after only 1 dose. Stop taking levofloxacin tablets and get emergency medical help right away if you have any of the following symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:<br></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>    </li>
<li>trouble breathing or swallowing    </li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, face    </li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>    </li>
<li>rapid heartbeat    </li>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> </li>
</ul>
<p><br><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> may happen in people taking levofloxacin tablets, even after only 1 dose. Stop taking levofloxacin tablets at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and call your healthcare provider. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> may be a sign of a more serious reaction to levofloxacin tablets.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver damage</span> (hepatotoxicity):</span> Hepatotoxicity can happen in people who take levofloxacin tablets. Call your healthcare provider right away if you have unexplained symptoms such as:<br></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>    </li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>    </li>
<li>loss of appetite    </li>
<li>light colored bowel movements    </li>
<li>dark colored urine    </li>
<li>yellowing of your skin or the whites of your eyes</li>
</ul>
<p><br>Stop taking levofloxacin tablets and tell your healthcare provider right away if you have yellowing of your skin or white part of your eyes, or if you have dark urine. These can be signs of a serious reaction to levofloxacin tablets (a liver problem).<br></p>
<ul class="Disc"><li>
<span class="Bold">Central Nervous System Effects. </span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported in people who take fluoroquinolone antibiotics including levofloxacin tablets. Tell your healthcare provider if you have a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Ask your healthcare provider whether taking levofloxacin tablets will change your risk of having a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. </li></ul>
<p><br>Central Nervous System (CNS) side effects may happen as soon as after taking the first dose of levofloxacin tablets. Talk to your healthcare provider right away if you get any of these side effects, or other changes in mood or behavior: </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>    </li>
<li>hear voices, see things, or sense things that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>)    </li>
<li>feel <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>    </li>
<li>feel anxious or nervous    </li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>    </li>
<li>trouble sleeping    </li>
<li><span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>    </li>
<li>feel lightheaded    </li>
<li>feel more suspicious (<span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>)    </li>
<li>suicidal thoughts or acts    </li>
<li>a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> that will not go away, with or without <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</li>
</ul>
<p><span class="Bold"></span></p>
<ul class="Disc"><li><span class="Bold">Intestine <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span>)</span></li></ul>
<p><br><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> can happen with many antibiotics, including levofloxacin tablets. Call your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">watery diarrhea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not go away, or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>. You may have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> can happen 2 or more months after you have finished your antibiotic.<br></p>
<ul class="Disc"><li><span class="Bold">Changes in sensation and possible <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> (<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>)</span></li></ul>
<p><br>Damage to the nerves in arms, hands, legs, or feet can happen in people taking fluoroquinolones, including levofloxacin tablets. Talk with your healthcare provider right away if you get any of the following symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> in your arms, hands, legs, or feet:<br></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>    </li>
<li>burning    </li>
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
</ul>
<p><br>Levofloxacin tablets may need to be stopped to prevent permanent <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>.<br></p>
<ul class="Disc"><li>
<span class="Bold">Serious heart rhythm changes </span><span class="Bold">(QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>)</span>
</li></ul>
<p><br>Tell your healthcare provider right away if you have a change in your heart beat (a fast or irregular heartbeat), or if you <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>. Levofloxacin tablets may cause a rare heart problem known as prolongation of the QT interval. This condition can cause an abnormal heartbeat and can be very dangerous. The chances of this happening are higher in people: <br></p>
<ul class="Disc">
<li>who are elderly    </li>
<li>with a family history of prolonged QT interval    </li>
<li>with low <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>)    </li>
<li>who take certain medicines to control heart rhythm (antiarrhythmics)</li>
</ul>
<ul class="Disc"><li><span class="Bold">Joint Problems </span></li></ul>
<p><br>Increased chance of problems with joints and tissues around joints in children can happen. Tell your child’s healthcare provider if your child has any joint problems during or after treatment with levofloxacin tablets.<br></p>
<ul class="Disc"><li><span class="Bold">Changes in blood sugar </span></li></ul>
<p><br>People who take levofloxacin tablets and other fluoroquinolone medicines with oral anti-<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines or with insulin can get low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) and high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>). Follow your healthcare provider’s instructions for how often to check your blood sugar. If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and you get low blood sugar while taking levofloxacin tablets, stop taking levofloxacin tablets and call your healthcare provider right away. Your antibiotic medicine may need to be changed.<br></p>
<ul class="Disc"><li><span class="Bold">Sensitivity to sunlight (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>)</span></li></ul>
<p><br>See <span class="Bold">“What should I avoid while taking levofloxacin tablets??</span><br><br>The most common side effects of levofloxacin tablets include:<br></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>    </li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </li>
</ul>
<p><br>In children 6 months and older who take levofloxacin tablets to treat <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> disease or <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> is also common. <br><br>Tell your healthcare provider if you feel dizzy or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> during a treatment with levofloxacin tablets. <br><br>Levofloxacin tablets may cause false-positive urine screening results for opiates when testing is done with some commercially available kits. A positive result should be confirmed using a more specific test. <br><br>These are not all the possible side effects of levofloxacin tablets. Tell your healthcare provider about any side effect that bothers you or that does not go away. <br><br>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. <br><br><span class="Bold">How should I store levofloxacin tablets?</span><br></p>
<ul class="Disc">
<li>Store <span class="Bold"></span>levofloxacin tablets at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].    </li>
<li>Keep levofloxacin tablets in a tightly closed container.</li>
</ul>
<p><br><span class="Bold">Keep levofloxacin tablets and all medicines out of the reach of children.</span><br><br><span class="Bold">General information about the safe and effective use of levofloxacin tablets<br><br></span>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use levofloxacin tablets for a condition for which it is not prescribed. Do not give levofloxacin tablets to other people, even if they have the same symptoms that you have. They may harm them. <br><br>This Medication Guide summarizes the most important information about levofloxacin tablets. If you would like more information about levofloxacin tablets, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about levofloxacin tablets that is written for healthcare professionals.<br><br>For more information call 1-866-850-2876.<span class="Bold"><br><br>What are the ingredients in levofloxacin tablets? <br><br></span>Active ingredient: levofloxacin   <br><br>Inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, polysorbate 80, and titanium dioxide. In addition 250 mg contains iron oxide red and 500 mg contains iron oxide red and iron oxide yellow<br><br>This Medication Guide has been approved by the U.S. Food and Drug Administration.<br><br>Manufactured for: <br><span class="Bold">Aurobindo Pharma USA, Inc.</span><br>2400 Route 130 North<br>Dayton, NJ 08810<br><br>Manufactured by:<br><span class="Bold">Aurobindo Pharma Limited</span><br>Unit-VII (SEZ)<br>Mahaboob Nagar (Dt)<br>AP-509302, INDIA<br><br>Revised: 06/2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_24"></a><a name="section-19"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 750 mg (20 Tablet Bottle)</h1>
<p class="First"><span class="Bold"><br><span class="Bold">Once-a-day                    </span><br></span><span class="Bold">Levofloxacin Tablets</span><br><span class="Bold">750 mg</span><br><span class="Bold">ATTENTION PHARMACIST: </span>Dispense the<br>accompanying Medication Guide to each patient<br><span class="Bold">Rx only                                          </span><br><img alt="43063459 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=814450ae-439e-4a5d-8c60-9b21b6f14be5&amp;name=43063459.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOFLOXACIN
                         		
					</strong><br><span class="contentTableReg">levofloxacin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43063-459(NDC:65862-538)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOFLOXACIN</strong> (LEVOFLOXACIN ANHYDROUS) </td>
<td class="formItem">LEVOFLOXACIN ANHYDROUS</td>
<td class="formItem">750 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (Biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">11;T</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:43063-459-05</td>
<td class="formItem">5  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:43063-459-07</td>
<td class="formItem">7  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:43063-459-10</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:43063-459-20</td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA201043</td>
<td class="formItem">06/20/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack(43063-459)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>910f9414-f323-42d3-8945-37d4b9beee03</div>
<div>Set id: 814450ae-439e-4a5d-8c60-9b21b6f14be5</div>
<div>Version: 7</div>
<div>Effective Time: 20120925</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
